{"protocolSection":{"identificationModule":{"nctId":"NCT01064687","orgStudyIdInfo":{"id":"11373"},"secondaryIdInfos":[{"id":"H9X-MC-GBDA","type":"OTHER","domain":"Eli Lilly and Company"}],"organization":{"fullName":"Eli Lilly and Company","class":"INDUSTRY"},"briefTitle":"A Study in Participants With Type 2 Diabetes Mellitus","officialTitle":"A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)","acronym":"AWARD-1"},"statusModule":{"statusVerifiedDate":"2015-01","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2010-02"},"primaryCompletionDateStruct":{"date":"2011-11","type":"ACTUAL"},"completionDateStruct":{"date":"2012-05","type":"ACTUAL"},"studyFirstSubmitDate":"2010-02-05","studyFirstSubmitQcDate":"2010-02-05","studyFirstPostDateStruct":{"date":"2010-02-08","type":"ESTIMATED"},"resultsFirstSubmitDate":"2014-10-03","resultsFirstSubmitQcDate":"2015-01-15","resultsFirstPostDateStruct":{"date":"2015-01-26","type":"ESTIMATED"},"dispFirstSubmitDate":"2012-02-10","dispFirstSubmitQcDate":"2012-02-10","dispFirstPostDateStruct":{"date":"2012-02-14","type":"ESTIMATED"},"lastUpdateSubmitDate":"2015-01-15","lastUpdatePostDateStruct":{"date":"2015-01-26","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Eli Lilly and Company","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"The purpose of this study is to determine if LY2189265 is effective and safe in reducing hemoglobin A1c (HbA1c), as compared to placebo (no medicine), or exenatide in participants with Type 2 Diabetes. The participants must also be taking metformin and pioglitazone.","detailedDescription":"During the study, if a participant developed persistent, severe hyperglycemia despite full compliance with the assigned therapeutic regimen, the participant received additional therapeutic intervention or initiation of an alternative antihyperglycemic medication following study drug discontinuation (rescue therapy). Participants who received rescue therapy were included in the analysis population, but only measurements obtained prior to the beginning of rescue therapy were included in specified analyses."},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":978,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"1.5 mg LY2189265","type":"EXPERIMENTAL","description":"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks","interventionNames":["Drug: LY2189265","Drug: Metformin","Drug: Pioglitazone"]},{"label":"0.75 mg LY2189265","type":"EXPERIMENTAL","description":"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks","interventionNames":["Drug: LY2189265","Drug: Metformin","Drug: Pioglitazone"]},{"label":"Exenatide","type":"ACTIVE_COMPARATOR","description":"Exenatide: 5 micrograms (mcg), subcutaneous (SC), twice daily for 4 weeks, followed by 10 mcg, SC, twice daily for 48 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks","interventionNames":["Drug: Exenatide","Drug: Metformin","Drug: Pioglitazone"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Placebo: subcutaneous (SC), once weekly for 26 weeks\n\nLY2189265 (Dulaglutide): After 26 weeks, participants were randomized to receive either 0.75 milligrams (mg) or 1.5 mg, SC, once weekly for an additional 26 weeks (from week 26 through week 52).\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks","interventionNames":["Drug: LY2189265","Drug: Placebo","Drug: Metformin","Drug: Pioglitazone"]}],"interventions":[{"type":"DRUG","name":"LY2189265","armGroupLabels":["0.75 mg LY2189265","1.5 mg LY2189265","Placebo"],"otherNames":["Dulaglutide"]},{"type":"DRUG","name":"Exenatide","armGroupLabels":["Exenatide"]},{"type":"DRUG","name":"Placebo","armGroupLabels":["Placebo"]},{"type":"DRUG","name":"Metformin","armGroupLabels":["0.75 mg LY2189265","1.5 mg LY2189265","Exenatide","Placebo"]},{"type":"DRUG","name":"Pioglitazone","armGroupLabels":["0.75 mg LY2189265","1.5 mg LY2189265","Exenatide","Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Change From Baseline to 26 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c)","description":"Least squares (LS) means were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline HbA1c as a covariate.","timeFrame":"Baseline, 26 weeks"}],"secondaryOutcomes":[{"measure":"Change From Baseline to 52 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c)","description":"Least squares (LS) means were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline HbA1c as a covariate.","timeFrame":"Baseline, 52 weeks"},{"measure":"Change From Baseline to 26 Weeks for Body Weight","description":"Least squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) analysis with treatment, country, visit, and treatment-by-visit as fixed effects and baseline as a covariate.","timeFrame":"Baseline, 26 weeks"},{"measure":"Change From Baseline to 52 Weeks for Body Weight","description":"Least squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) analysis with treatment, country, visit, and treatment-by-visit as fixed effects and baseline as a covariate.","timeFrame":"Baseline, 52 weeks"},{"measure":"Change From Baseline to 26 Weeks on Body Mass Index (BMI)","description":"Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.","timeFrame":"Baseline, 26 weeks"},{"measure":"Change From Baseline to 52 Weeks on Body Mass Index (BMI)","description":"Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.","timeFrame":"Baseline, 52 weeks"},{"measure":"Change From Baseline to 26 Weeks for Daily Mean Blood Glucose Values From the 8-point Self-monitored Plasma Glucose (SMPG) Profiles","description":"The SMPG data were collected at the following 8 time points: pre-morning meal; 2 hours post-morning meal; pre-midday meal; 2 hours post-midday meal; pre-evening; 2 hours post-evening meal; bedtime; and 3AM or 5 hours after bedtime. Least squares (LS) means of the mean of the 8 time points (daily mean) were calculated using a mixed-effects model for repeated measures (MMRM) analysis with treatment, country, visit, and treatment-by-visit as fixed effects and baseline as a covariate.","timeFrame":"Baseline, 26 weeks"},{"measure":"Change From Baseline to 52 Weeks for Daily Mean Blood Glucose Values From the 8-point Self-monitored Plasma Glucose (SMPG) Profiles","description":"The SMPG data were collected at the following 8 time points: pre-morning meal; 2 hours post-morning meal; pre-midday meal; 2 hours post-midday meal; pre-evening; 2 hours post-evening meal; bedtime; and 3AM or 5 hours after bedtime. Least squares (LS) means of the mean of the 8 time points (daily mean) were calculated using a mixed-effects model for repeated measures (MMRM) analysis with treatment, country, visit, and treatment-by-visit as fixed effects and baseline as a covariate.","timeFrame":"Baseline, 52 weeks"},{"measure":"Percentage of Participants Attaining Glycosylated Hemoglobin (HbA1c) Less Than 7% and Less Than or Equal to 6.5% at 26 Weeks","description":"The percentage of participants achieving HbA1c level less than 7.0% and less than or equal to 6.5% was analyzed with a logistic regression model with baseline, country, and treatment as factors included in the model.","timeFrame":"Baseline, 26 weeks"},{"measure":"Percentage of Participants Attaining Glycosylated Hemoglobin (HbA1c) Less Than 7% and Less Than or Equal to 6.5% at 52 Weeks","description":"The percentage of participants achieving HbA1c level less than 7.0% and less than or equal to 6.5% was analyzed with a logistic regression model with baseline, country, and treatment as factors included in the model.","timeFrame":"Baseline, 52 weeks"},{"measure":"Change From Baseline to 26 Weeks in Updated Homeostasis Model Assessment of Beta-cell Function (HOMA2-%B) and Updated Homeostasis Model Assessment of Insulin Sensitivity (HOMA2-%S)","description":"The homeostatic model assessment (HOMA) quantifies insulin resistance and beta-cell function. HOMA2-B is a computer model that uses fasting plasma insulin and glucose concentrations to estimate steady-state beta cell function (%B) as a percentage of a normal reference population (normal young adults). HOMA2-S is a computer model that uses fasting plasma insulin and glucose concentrations to estimate insulin sensitivity (%S) as percentages of a normal reference population (normal young adults). The normal reference populations were set at 100%. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.","timeFrame":"Baseline, 26 weeks"},{"measure":"Change From Baseline to 52 Weeks in Updated Homeostasis Model Assessment of Beta-cell Function (HOMA2-%B) and Updated Homeostasis Model Assessment of Insulin Sensitivity (HOMA2-%S)","description":"The homeostatic model assessment (HOMA) quantifies insulin resistance and beta-cell function. HOMA2-B is a computer model that uses fasting plasma insulin and glucose concentrations to estimate steady-state beta cell function (%B) as a percentage of a normal reference population (normal young adults). HOMA2-S is a computer model that uses fasting plasma insulin and glucose concentrations to estimate insulin sensitivity (%S) as percentages of a normal reference population (normal young adults). The normal reference populations were set at 100%. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.","timeFrame":"Baseline, 52 weeks"},{"measure":"Change From Baseline to 26 Weeks in the EuroQol 5","description":"The European Quality of Life - 5 dimensions (EQ-5D) questionnaire is a generic, multidimensional, health-related, quality-of-life instrument. It consists of 2 parts: the first part assesses 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) that have 3 possible levels of response (no problem, some problem, or extreme problem). These dimensions are converted into a weighted health-state Index Score. The EQ-5D United Kingdom (UK) score ranges from -0.59 to 1.0, where a score of 1.0 indicates perfect health and negative values are valued as worse than dead. The second part of the questionnaire consists of a visual analog scale (VAS) on which the participants rated their perceived health state on that day from 0 (worst imaginable health state) to 100 (best imaginable health). Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) and adjusted by treatment, country, and baseline.","timeFrame":"Baseline, 26 weeks"},{"measure":"Change From Baseline to 52 Weeks in the EuroQol 5","description":"The European Quality of Life - 5 dimensions (EQ-5D) questionnaire is a generic, multidimensional, health-related, quality-of-life instrument. It consists of 2 parts: the first part assesses 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) that have 3 possible levels of response (no problem, some problem, or extreme problem). These dimensions are converted into a weighted health-state Index Score. The EQ-5D United Kingdom (UK) score ranges from -0.59 to 1.0, where a score of 1.0 indicates perfect health and negative values are valued as worse than dead. The second part of the questionnaire consists of a visual analog scale (VAS) on which the participants rated their perceived health state on that day from 0 (worst imaginable health state) to 100 (best imaginable health). Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) and adjusted by treatment, country, and baseline.","timeFrame":"Baseline, 52 weeks"},{"measure":"Change From Baseline to 26 Weeks in the Diabetes Treatment Satisfaction Questionnaire Status (DTSQs) Version","description":"The Diabetes Treatment Satisfaction Questionnaire status version (DTSQs) is used to assess participant treatment satisfaction at each study visit. The questionnaire consists of 8 items, 6 of which (1, and 4 through 8) assess treatment satisfaction. Each item is rated on a 7-point Likert scale. Scores from the 6 treatment satisfaction items are summed to a Total Treatment Satisfaction Score, which ranges from 0 (very dissatisfied) to 36 (very satisfied). The DTSQ change version (DTSQc) was not collected at 26 weeks. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline score as a covariate.","timeFrame":"Baseline, 26 weeks"},{"measure":"Change From Baseline to 52 Weeks in the Diabetes Treatment Satisfaction Questionnaire Status (DTSQs) and Change (DTSQc) Versions","description":"The Diabetes Treatment Satisfaction Questionnaire status (DTSQs) and change (DTSQc) versions are used to assess participant treatment satisfaction at each study visit and relative change in satisfaction from baseline, respectively. Both questionnaires consist of 8 items, 6 of which (1, and 4 through 8) assess treatment satisfaction. Each item is rated on a 7-point Likert scale. The change version has the same 8 items as the status version with a small alteration of the wording of Item 7. Scores from the 6 treatment satisfaction items are summed to a Total Treatment Satisfaction Score, which ranges from 0 (very dissatisfied) to 36 (very satisfied) for the DTSQs and from -18 (much less satisfied) to +18 (much more satisfied) for the DTSQc. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline score as a covariate.","timeFrame":"Baseline, 52 weeks"},{"measure":"Change From Baseline to 26 Weeks in the Impact of Weight on Activities of Daily Living","description":"The Impact of Weight on Activities of Daily Living (renamed the Ability to Perform Physical Activities of Daily Living \\[APPADL\\]) questionnaire contains 7 items that assess how difficult it is for participants to engage in certain activities considered to be integral to normal daily life, such as walking, standing and climbing stairs. Items are scored on a 5-point numeric rating scale where 5 = \"not at all difficult\" and 1 = \"unable to do\". The individual scores from all 7 items are summed and a single total score is calculated and may range between 7 and 35. A higher score indicates better ability to perform activities of daily living. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline as a covariate.","timeFrame":"Baseline, 26 weeks"},{"measure":"Change From Baseline to 52 Weeks in the Impact of Weight on Activities of Daily Living","description":"The Impact of Weight on Activities of Daily Living (renamed the Ability to Perform Physical Activities of Daily Living \\[APPADL\\]) questionnaire contains 7 items that assess how difficult it is for participants to engage in certain activities considered to be integral to normal daily life, such as walking, standing and climbing stairs. Items are scored on a 5-point numeric rating scale where 5 = \"not at all difficult\" and 1 = \"unable to do\". The individual scores from all 7 items are summed and a single total score is calculated and may range between 7 and 35. A higher score indicates better ability to perform activities of daily living. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline as a covariate.","timeFrame":"Baseline, 52 weeks"},{"measure":"Change From Baseline to 26 Weeks on the Impact of Weight on Self-Perception","description":"The Impact of Weight on Self-Perception (IW-SP) questionnaire contains 3 items that assess how often the participants' body weight affects how happy they are with their appearance and how often they feel self-conscious when out in public. Items are scored on a 5-point numeric rating scale where 5 = never and 1 = always. A single total score is calculated by summing the scores for all 3 items. Total score ranges between 3 and 15, where a higher score is indicative of better self-perception. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline as a covariate.","timeFrame":"Baseline, 26 weeks"},{"measure":"Change From Baseline to 52 Weeks on the Impact of Weight on Self-Perception","description":"The Impact of Weight on Self-Perception (IW-SP) questionnaire contains 3 items that assess how often the participants' body weight affects how happy they are with their appearance and how often they feel self-conscious when out in public. Items are scored on a 5-point numeric rating scale where 5 = never and 1 = always. A single total score is calculated by summing the scores for all 3 items. Total score ranges between 3 and 15, where a higher score is indicative of better self-perception. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline as a covariate.","timeFrame":"Baseline, 52 weeks"},{"measure":"Number of Participants With Adjudicated Cardiovascular Events at 52 Weeks","description":"Information on cardiovascular (CV) risk factors was collected at baseline. Data on any new CV event was prospectively collected using a CV event electronic case report form. At prespecified visits, participants were asked about any new CV event since the previous inquiry. Deaths and nonfatal cardiovascular adverse events (AEs) were adjudicated by an external committee of physicians with cardiology expertise. Nonfatal cardiovascular AEs to be adjudicated included myocardial infarction, hospitalization for unstable angina, hospitalization for heart failure, coronary interventions, and cerebrovascular events, including cerebrovascular accident (stroke) and transient ischemic attack. The number of participants with CV events confirmed by adjudication is summarized cumulatively at 52 weeks. Serious and all other non-serious adverse events regardless of causality are summarized in the Reported Adverse Events module.","timeFrame":"Baseline through 52 weeks"},{"measure":"Change From Baseline to 26 Weeks on Electrocardiogram Parameters, Fridericia Corrected QT (QTcF) Interval and PR Interval","description":"The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTc = QT/RR\\^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. PR is the interval between the P wave and the QRS complex. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.","timeFrame":"Baseline, 26 weeks"},{"measure":"Change From Baseline to 52 Weeks on Electrocardiogram Parameters, Fridericia Corrected QT (QTcF) Interval and PR Interval","description":"The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTc = QT/RR\\^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. PR is the interval between the P wave and the QRS complex. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.","timeFrame":"Baseline, 52 weeks"},{"measure":"Change in Baseline to 26 Weeks on Pulse Rate","description":"Seated pulse rate was measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.","timeFrame":"Baseline, 26 weeks"},{"measure":"Change in Baseline to 52 Weeks on Pulse Rate","description":"Seated pulse rate was measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.","timeFrame":"Baseline, 52 weeks"},{"measure":"Change From Baseline to 26 Weeks on Blood Pressure","description":"Seated systolic blood pressure (SBP) and seated diastolic blood pressure (DBP) were measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.","timeFrame":"Baseline, 26 weeks"},{"measure":"Change From Baseline to 52 Weeks on Blood Pressure","description":"Seated systolic blood pressure (SBP) and seated diastolic blood pressure (DBP) were measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.","timeFrame":"Baseline, 52 weeks"},{"measure":"Number of Participants With Adjudicated Pancreatitis at 26 Weeks","description":"The number of participants with pancreatitis confirmed by adjudication is summarized cumulatively at 26 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.","timeFrame":"Baseline through 26 weeks"},{"measure":"Number of Participants With Adjudicated Pancreatitis at 52 Weeks","description":"The number of participants with pancreatitis confirmed by adjudication is summarized cumulatively at 52 weeks, with the exception of the Placebo/1.5 mg LY2189265 and Placebo/0.75 mg LY2189265 treatment groups, which include only participants with confirmed pancreatitis during treatment with LY2189265 (26 weeks through 52 weeks). A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.","timeFrame":"Baseline through 52 weeks"},{"measure":"Change From Baseline to 26 Weeks on Pancreatic Enzymes","description":"Amylase (total and pancreas-derived) and lipase concentrations were measured.","timeFrame":"Baseline, 26 weeks"},{"measure":"Change From Baseline to 52 Weeks on Pancreatic Enzymes","description":"Amylase (total and pancreas-derived) and lipase concentrations were measured.","timeFrame":"Baseline, 52 weeks"},{"measure":"Change From Baseline to 26 Weeks on Serum Calcitonin","timeFrame":"Baseline, 26 weeks"},{"measure":"Change From Baseline to 52 Weeks on Serum Calcitonin","timeFrame":"Baseline, 52 weeks"},{"measure":"Number of Self-reported Hypoglycemic Events at 26 Weeks","description":"Hypoglycemic events (HE) were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of less than or equal to 3.9 millimoles/liter \\[mmol/L\\]), asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of less than or equal to 3.9 mmol/L), nocturnal (defined as any hypoglycemic event that occurred between bedtime and waking), or probable symptomatic (defined as events during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). The number of self-reported hypoglycemic events is summarized cumulatively at 26 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.","timeFrame":"Baseline through 26 weeks"},{"measure":"Number of Self-reported Hypoglycemic Events at 52 Weeks","description":"Hypoglycemic events (HE) were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of less than or equal to 3.9 millimoles/liter \\[mmol/L\\]), asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of less than or equal to 3.9 mmol/L), nocturnal (defined as any hypoglycemic event that occurred between bedtime and waking), or probable symptomatic (defined as events during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). The number of self-reported hypoglycemic events is summarized cumulatively at 52 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.","timeFrame":"Baseline through 52 weeks"},{"measure":"Rate of Self-reported Hypoglycemic Events at 26 Weeks","description":"Hypoglycemic events (HE) were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of equal to or less than 3.9 millimoles/liter \\[mmol/L\\]), asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of equal to or less than 3.9 mmol/L), nocturnal (defined as any hypoglycemic event that occurred between bedtime and waking), or probable symptomatic (defined as events during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). The 1-year adjusted rate of hypoglycemic events is summarized cumulatively at 26 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.","timeFrame":"Baseline through 26 weeks"},{"measure":"Rate of Self-reported Hypoglycemic Events at 52 Weeks","description":"Hypoglycemic events (HE) were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of equal to or less than millimoles/liter \\[mmol/L\\]), asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of equal to or less than 3.9 mmol/L), nocturnal (defined as any hypoglycemic event that occurred between bedtime and waking), or probable symptomatic (defined as events during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). The 1-year adjusted rate of hypoglycemic events is summarized cumulatively at 52 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.","timeFrame":"Baseline through 52 weeks"},{"measure":"Number of Participants Requiring Rescue Therapy Due to Hyperglycemia at 26 Weeks","description":"Rescue therapy was defined as any additional therapeutic intervention in participants who developed persistent, severe hyperglycemia despite full compliance with the assigned therapeutic regimen, or initiation of an alternative antihyperglycemic medication following study drug discontinuation. Participants who had no rescue therapy within specified study period were considered as censored observations at the last available contact date up to specified study period. Time to start first new glucose-lowering intervention due to hyperglycemia (\"rescue therapy\") was analyzed between the groups using the semi-parametric proportional hazard regression model with treatment group and country as fixed effects and baseline glycosylated hemoglobin (HbA1c) as a covariate.","timeFrame":"Baseline through 26 weeks"},{"measure":"Number of Participants Requiring Rescue Therapy Due to Hyperglycemia at 52 Weeks","description":"Rescue therapy was defined as any additional therapeutic intervention in participants who developed persistent, severe hyperglycemia despite full compliance with the assigned therapeutic regimen, or initiation of an alternative antihyperglycemic medication following study drug discontinuation. Participants who had no rescue therapy within specified study period were considered as censored observations at the last available contact date up to specified study period. Time to start first new glucose-lowering intervention due to hyperglycemia (\"rescue therapy\") was analyzed between the groups using the semi-parametric proportional hazard regression model with treatment group and country as fixed effects and baseline glycosylated hemoglobin (HbA1c) as a covariate.","timeFrame":"Baseline through 52 weeks"},{"measure":"Number of Participants With LY2189265 Antibodies at 26 Weeks","description":"LY2189265 (Dulaglutide) anti-drug antibodies (ADA) were assessed. The number of participants with initial postbaseline detection of treatment emergent (defined as a 4-fold increase in the ADA titer from baseline) LY2189265 ADA were summarized.","timeFrame":"Baseline through 26 weeks"},{"measure":"Number of Participants With LY2189265 Antibodies at 52 Weeks and 4 Weeks After Last Dose of Study Drug","description":"LY2189265 (Dulaglutide) anti-drug antibodies (ADA) were assessed. The number of participants with initial postbaseline detection of treatment emergent (defined as a 4-fold increase in the ADA titer from baseline) LY2189265 ADA were summarized.","timeFrame":"26 weeks through 52 weeks and 53 weeks through 4 weeks after last dose"},{"measure":"Number of Participants With Treatment Emergent Adverse Events at 26 Weeks","description":"A treatment-emergent adverse event (TEAE) was defined as an event that first occurs or worsens (increases in severity) after baseline regardless of causality or severity. The number of participants with one or more TEAE is summarized cumulatively at 26 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.","timeFrame":"Baseline through 26 weeks"},{"measure":"Number of Participants With Treatment Emergent Adverse Events at 52 Weeks","description":"A treatment-emergent adverse event (TEAE) was defined as an event that first occurs or worsens (increases in severity) after baseline regardless of causality or severity. The number of participants with one or more TEAE is summarized cumulatively at 52 weeks, with the exception of the Placebo/1.5 mg LY2189265 and Placebo/0.75 mg LY2189265 treatment groups, which include only TEAEs that occurred during treatment with LY2189265 (26 weeks through 52 weeks). A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.","timeFrame":"Baseline through 52 weeks"},{"measure":"Change From Baseline to 26 Weeks in Hematological and Biochemical Lab Values","timeFrame":"Baseline, 26 weeks"},{"measure":"Change From Baseline to 52 Weeks in Hematological and Biochemical Lab Values","timeFrame":"Baseline, 52 weeks"},{"measure":"Change From Baseline to 26 Weeks in N Terminal Pro Brain Natriuretic Peptide (NT-proBNP)","timeFrame":"Baseline, 26 weeks"},{"measure":"Pharmacokinetics: Area Under the Concentration Curve (AUC) for LY2189265","description":"Evaluable pharmacokinetic concentrations from the 4-week, 13-week, 26-week, and 52-week timepoints were combined and utilized in a population approach to determine the population mean estimate and standard deviation at steady-state.","timeFrame":"4 weeks, 13 weeks, 26 weeks, and 52 weeks"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Type 2 Diabetes (T2D) not well controlled on 1, 2, or 3 oral antidiabetic medications\n\n  1. Glycosylated hemoglobin (HbA1c) greater than or equal to 7 and less than or equal to 11 if taking 1 oral antidiabetic medication\n  2. HbA1c greater than or equal to 7 and less than or equal to 10 if on 2 or 3 oral antidiabetic medications\n* Able to tolerate minimum dose of 1500 milligrams (mg) metformin a day and 30 mg pioglitazone per day.\n* Willing to inject subcutaneous (SC) medication up to 2 times per day\n* Stable weight for 3 months prior to screening\n* Body mass index (BMI) between 23 and 45 kilograms per meter squared (kg/m\\^2)\n* Females of child bearing potential must test negative for pregnancy at screening by serum pregnancy test and be willing to use a reliable method of birth control during the study and for 1 month following the last dose of study drug.\n\nExclusion Criteria:\n\n* Type 1 Diabetes\n* HbA1c equal to or less than 6.5 before randomization or at randomization\n* Chronic insulin use\n* Taking drugs to promote weight loss by prescription or over the counter\n* Taking systemic steroids for greater than 14 days except for topical, eye, nasal, or inhaled\n* History of fluid retention or edema\n* History of Heart Failure New York Heart Classification II, III, or IV or acute myocardial infarction or stroke within 2 months of screening\n* Gastrointestinal (GI; stomach) problems such as diabetic gastroparesis or bariatric surgery (stomach stapling) or chronically taking drugs that directly affect GI motility\n* Hepatitis or liver disease or alanine transaminase (ALT) greater than 2.5 times the upper limit of normal\n* Acute or chronic pancreatitis of any form\n* Renal disease (kidney) with a serum creatinine of greater than or equal to 1.5 milligrams per deciliter (mg/dL) for males and greater than or equal to 1.4 mg/dL for females, or a creatine clearance of less than 60 milliliters per minute (mL/min)\n* History (includes family) of type 2A or 2B Multiple Endocrine Neoplasia (MEN 2A or 2B) or medullary c-cell hyperplasia or thyroid cancer\n* A serum calcitonin greater than or equal to 20 picograms per milliliter (pg/mL) at screening\n* Significant active autoimmune disease such as Lupus or Rheumatoid Arthritis\n* History of or active malignancy except skin or in situ cervical or prostate cancer for within last 5 years\n* Sickle cell, hemolytic anemia, or other hematological condition that may interfere with HbA1c testing\n* Organ transplant except cornea\n* Have enrolled in another clinical trial within the last 30 days\n* Have previously signed an informed consent or participated in a LY2189265 (dulaglutide) study\n* Have taken a glucagon-like peptide 1 (GLP-1) receptor agonist within the 3 months prior to screening","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)","affiliation":"Eli Lilly and Company","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Goodyear","state":"Arizona","zip":"85395","country":"United States","geoPoint":{"lat":33.43532,"lon":-112.35821}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Phoenix","state":"Arizona","zip":"85028","country":"United States","geoPoint":{"lat":33.44838,"lon":-112.07404}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Cathedral City","state":"California","zip":"92234","country":"United States","geoPoint":{"lat":33.77974,"lon":-116.46529}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Concord","state":"California","zip":"94520","country":"United States","geoPoint":{"lat":37.97798,"lon":-122.03107}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Fresno","state":"California","zip":"93720","country":"United States","geoPoint":{"lat":36.74773,"lon":-119.77237}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Greenbrae","state":"California","zip":"94904","country":"United States","geoPoint":{"lat":37.94854,"lon":-122.5247}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Lancaster","state":"California","zip":"93534","country":"United States","geoPoint":{"lat":34.69804,"lon":-118.13674}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Mission Hills","state":"California","zip":"91345","country":"United States","geoPoint":{"lat":34.68609,"lon":-120.43683}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Monterey","state":"California","zip":"93940","country":"United States","geoPoint":{"lat":36.60024,"lon":-121.89468}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"National City","state":"California","zip":"91950","country":"United States","geoPoint":{"lat":32.67811,"lon":-117.0992}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Oceanside","state":"California","zip":"92056","country":"United States","geoPoint":{"lat":33.19587,"lon":-117.37948}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Paramount","state":"California","zip":"90723","country":"United States","geoPoint":{"lat":33.88946,"lon":-118.15979}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Roseville","state":"California","zip":"95661","country":"United States","geoPoint":{"lat":38.75212,"lon":-121.28801}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"San Ramon","state":"California","zip":"94583","country":"United States","geoPoint":{"lat":37.77993,"lon":-121.97802}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Tustin","state":"California","zip":"92780","country":"United States","geoPoint":{"lat":33.74585,"lon":-117.82617}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"New Britain","state":"Connecticut","zip":"06050","country":"United States","geoPoint":{"lat":41.66121,"lon":-72.77954}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Fort Lauderdale","state":"Florida","zip":"33316","country":"United States","geoPoint":{"lat":26.12231,"lon":-80.14338}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Hollywood","state":"Florida","zip":"33021","country":"United States","geoPoint":{"lat":26.0112,"lon":-80.14949}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Orlando","state":"Florida","zip":"32806","country":"United States","geoPoint":{"lat":28.53834,"lon":-81.37924}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Pembroke Pines","state":"Florida","zip":"33027","country":"United States","geoPoint":{"lat":26.00315,"lon":-80.22394}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"West Palm Beach","state":"Florida","zip":"33401","country":"United States","geoPoint":{"lat":26.71534,"lon":-80.05337}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Atlanta","state":"Georgia","zip":"30308","country":"United States","geoPoint":{"lat":33.749,"lon":-84.38798}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Honolulu","state":"Hawaii","zip":"96813","country":"United States","geoPoint":{"lat":21.30694,"lon":-157.85833}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Boise","state":"Idaho","zip":"83702","country":"United States","geoPoint":{"lat":43.6135,"lon":-116.20345}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Idaho Falls","state":"Idaho","zip":"83404","country":"United States","geoPoint":{"lat":43.46658,"lon":-112.03414}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Meridian","state":"Idaho","zip":"83646","country":"United States","geoPoint":{"lat":43.61211,"lon":-116.39151}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Crystal Lake","state":"Illinois","zip":"60012","country":"United States","geoPoint":{"lat":42.24113,"lon":-88.3162}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Peoria","state":"Illinois","zip":"61615","country":"United States","geoPoint":{"lat":40.69365,"lon":-89.58899}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Vincennes","state":"Indiana","zip":"47591","country":"United States","geoPoint":{"lat":38.67727,"lon":-87.52863}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Topeka","state":"Kansas","zip":"66606","country":"United States","geoPoint":{"lat":39.04833,"lon":-95.67804}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Madisonville","state":"Kentucky","zip":"42431","country":"United States","geoPoint":{"lat":37.3281,"lon":-87.49889}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"New Orleans","state":"Louisiana","zip":"70112","country":"United States","geoPoint":{"lat":29.95465,"lon":-90.07507}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Bangor","state":"Maine","zip":"04401","country":"United States","geoPoint":{"lat":44.79884,"lon":-68.77265}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Biddeford","state":"Maine","zip":"04005","country":"United States","geoPoint":{"lat":43.49258,"lon":-70.45338}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Elkridge","state":"Maryland","zip":"21075","country":"United States","geoPoint":{"lat":39.21261,"lon":-76.71358}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Bloomfield Hills","state":"Michigan","zip":"48302","country":"United States","geoPoint":{"lat":42.58364,"lon":-83.24549}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Flint","state":"Michigan","zip":"48503","country":"United States","geoPoint":{"lat":43.01253,"lon":-83.68746}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"St Louis","state":"Missouri","zip":"63141","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Nashua","state":"New Hampshire","zip":"03063","country":"United States","geoPoint":{"lat":42.76537,"lon":-71.46757}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Toms River","state":"New Jersey","zip":"08753","country":"United States","geoPoint":{"lat":39.95373,"lon":-74.19792}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Albany","state":"New York","zip":"12206","country":"United States","geoPoint":{"lat":42.65258,"lon":-73.75623}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Flushing","state":"New York","zip":"11365","country":"United States","geoPoint":{"lat":40.76538,"lon":-73.81736}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Syracuse","state":"New York","zip":"13210","country":"United States","geoPoint":{"lat":43.04812,"lon":-76.14742}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Asheville","state":"North Carolina","zip":"28803","country":"United States","geoPoint":{"lat":35.60095,"lon":-82.55402}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Cary","state":"North Carolina","zip":"27518","country":"United States","geoPoint":{"lat":35.79154,"lon":-78.78112}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Durham","state":"North Carolina","zip":"27713","country":"United States","geoPoint":{"lat":35.99403,"lon":-78.89862}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Morehead City","state":"North Carolina","zip":"28557","country":"United States","geoPoint":{"lat":34.72294,"lon":-76.72604}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Cincinnati","state":"Ohio","zip":"45242","country":"United States","geoPoint":{"lat":39.12711,"lon":-84.51439}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Cleveland","state":"Ohio","zip":"44122","country":"United States","geoPoint":{"lat":41.4995,"lon":-81.69541}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Columbus","state":"Ohio","zip":"43210","country":"United States","geoPoint":{"lat":39.96118,"lon":-82.99879}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Dayton","state":"Ohio","zip":"45439","country":"United States","geoPoint":{"lat":39.75895,"lon":-84.19161}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Delaware","state":"Ohio","zip":"43015","country":"United States","geoPoint":{"lat":40.29867,"lon":-83.06797}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Perrysburg","state":"Ohio","zip":"43551","country":"United States","geoPoint":{"lat":41.557,"lon":-83.62716}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Bend","state":"Oregon","zip":"97701","country":"United States","geoPoint":{"lat":44.05817,"lon":-121.31531}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Corvallis","state":"Oregon","zip":"97330","country":"United States","geoPoint":{"lat":44.56457,"lon":-123.26204}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Eugene","state":"Oregon","zip":"97401","country":"United States","geoPoint":{"lat":44.05207,"lon":-123.08675}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Beaver","state":"Pennsylvania","zip":"15009","country":"United States","geoPoint":{"lat":40.69534,"lon":-80.30478}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Danville","state":"Pennsylvania","zip":"17822","country":"United States","geoPoint":{"lat":40.96342,"lon":-76.61273}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Levittown","state":"Pennsylvania","zip":"19056","country":"United States","geoPoint":{"lat":40.15511,"lon":-74.82877}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Philadelphia","state":"Pennsylvania","zip":"19107","country":"United States","geoPoint":{"lat":39.95238,"lon":-75.16362}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Wilkes-Barre","state":"Pennsylvania","zip":"18711","country":"United States","geoPoint":{"lat":41.24591,"lon":-75.88131}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Charleston","state":"South Carolina","zip":"29412","country":"United States","geoPoint":{"lat":32.77632,"lon":-79.93275}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Greenville","state":"South Carolina","zip":"29605","country":"United States","geoPoint":{"lat":34.85262,"lon":-82.39401}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Greer","state":"South Carolina","zip":"29651","country":"United States","geoPoint":{"lat":34.93873,"lon":-82.22706}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Myrtle Beach","state":"South Carolina","zip":"29572","country":"United States","geoPoint":{"lat":33.68906,"lon":-78.88669}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Memphis","state":"Tennessee","zip":"38119","country":"United States","geoPoint":{"lat":35.14953,"lon":-90.04898}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Arlington","state":"Texas","zip":"76014","country":"United States","geoPoint":{"lat":32.73569,"lon":-97.10807}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Austin","state":"Texas","zip":"78731","country":"United States","geoPoint":{"lat":30.26715,"lon":-97.74306}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Corpus Christi","state":"Texas","zip":"78404","country":"United States","geoPoint":{"lat":27.80058,"lon":-97.39638}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Dallas","state":"Texas","zip":"75231","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"El Paso","state":"Texas","zip":"79925","country":"United States","geoPoint":{"lat":31.75872,"lon":-106.48693}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"San Antonio","state":"Texas","zip":"78258","country":"United States","geoPoint":{"lat":29.42412,"lon":-98.49363}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Schertz","state":"Texas","zip":"78154","country":"United States","geoPoint":{"lat":29.55217,"lon":-98.26973}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Ogden","state":"Utah","zip":"84403","country":"United States","geoPoint":{"lat":41.223,"lon":-111.97383}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"St. George","state":"Utah","zip":"84790","country":"United States","geoPoint":{"lat":37.10415,"lon":-113.58412}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"West Jordan","state":"Utah","zip":"84088","country":"United States","geoPoint":{"lat":40.60967,"lon":-111.9391}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Spokane","state":"Washington","zip":"99202","country":"United States","geoPoint":{"lat":47.65966,"lon":-117.42908}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Tacoma","state":"Washington","zip":"98405","country":"United States","geoPoint":{"lat":47.25288,"lon":-122.44429}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Buenos Aires","zip":"CBA 1419","country":"Argentina","geoPoint":{"lat":-34.61315,"lon":-58.37723}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Guadalajara","zip":"44600","country":"Mexico","geoPoint":{"lat":20.67738,"lon":-103.34749}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Mexico City","zip":"6700","country":"Mexico","geoPoint":{"lat":19.42847,"lon":-99.12766}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Monterrey","zip":"64461","country":"Mexico","geoPoint":{"lat":25.68435,"lon":-100.31721}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Caguas","zip":"00726","country":"Puerto Rico","geoPoint":{"lat":18.23412,"lon":-66.0485}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Hato Rey","zip":"00917","country":"Puerto Rico"},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Manati","zip":"00674","country":"Puerto Rico","geoPoint":{"lat":18.42745,"lon":-66.49212}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Ponce","zip":"00716","country":"Puerto Rico","geoPoint":{"lat":18.01031,"lon":-66.62398}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"San German","zip":"00683","country":"Puerto Rico","geoPoint":{"lat":18.08163,"lon":-67.0449}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"San Juan","zip":"00907","country":"Puerto Rico","geoPoint":{"lat":18.46633,"lon":-66.10572}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Yabucoa","zip":"00767","country":"Puerto Rico","geoPoint":{"lat":18.05052,"lon":-65.87933}}]},"referencesModule":{"references":[{"pmid":"36894938","type":"DERIVED","citation":"Ferdinand KC, Dunn J, Nicolay C, Sam F, Blue EK, Wang H. Weight-dependent and weight-independent effects of dulaglutide on blood pressure in patients with type 2 diabetes. Cardiovasc Diabetol. 2023 Mar 9;22(1):49. doi: 10.1186/s12933-023-01775-x."},{"pmid":"27161178","type":"DERIVED","citation":"Boustani MA, Pittman I 4th, Yu M, Thieu VT, Varnado OJ, Juneja R. Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged >/=65 and <65 years. Diabetes Obes Metab. 2016 Aug;18(8):820-8. doi: 10.1111/dom.12687. Epub 2016 Jun 7."},{"pmid":"26691396","type":"DERIVED","citation":"Yu M, Van Brunt K, Varnado OJ, Boye KS. Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme. Diabetes Obes Metab. 2016 Apr;18(4):419-24. doi: 10.1111/dom.12624. Epub 2016 Feb 4."}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Due to ethical considerations and to preserve the blinding of the study, participants randomized to placebo at baseline were reassigned at 26 weeks to either 1.5 mg LY2189265 or 0.75 mg LY2189265 from 26 weeks through 52 weeks.","groups":[{"id":"FG000","title":"1.5 mg LY2189265","description":"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"FG001","title":"0.75 mg LY2189265","description":"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"FG002","title":"Exenatide","description":"Exenatide: 5 micrograms (mcg), subcutaneous (SC), twice daily for 4 weeks, followed by 10 mcg, SC, twice daily for 48 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"FG003","title":"Placebo","description":"Placebo: subcutaneous (SC), once weekly for 26 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 26 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 26 weeks"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"279"},{"groupId":"FG001","numSubjects":"280"},{"groupId":"FG002","comment":"Of 278 participants randomized to Exenatide, 2 chose not to take study drug.","numSubjects":"278"},{"groupId":"FG003","numSubjects":"141"}]},{"type":"Received at Least 1 Dose of Study Drug","achievements":[{"groupId":"FG000","numSubjects":"279"},{"groupId":"FG001","numSubjects":"280"},{"groupId":"FG002","numSubjects":"276"},{"groupId":"FG003","numSubjects":"141"}]},{"type":"Completed 26 Weeks","achievements":[{"groupId":"FG000","numSubjects":"260"},{"groupId":"FG001","numSubjects":"263"},{"groupId":"FG002","numSubjects":"252"},{"groupId":"FG003","numSubjects":"124"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"245"},{"groupId":"FG001","numSubjects":"254"},{"groupId":"FG002","numSubjects":"237"},{"groupId":"FG003","numSubjects":"124"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"34"},{"groupId":"FG001","numSubjects":"26"},{"groupId":"FG002","numSubjects":"41"},{"groupId":"FG003","numSubjects":"17"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"10"},{"groupId":"FG003","numSubjects":"3"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"Entry Criteria Not Met","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"Lack of Efficacy","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"3"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"10"},{"groupId":"FG002","numSubjects":"13"},{"groupId":"FG003","numSubjects":"5"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"}]},{"type":"Sponsor Decision","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"7"},{"groupId":"FG002","numSubjects":"12"},{"groupId":"FG003","numSubjects":"5"}]},{"type":"Treatment Noncompliance","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Participants who were randomized and received at least 1 dose of LY2189265, Exenatide, or Placebo.","groups":[{"id":"BG000","title":"1.5 mg LY2189265","description":"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"BG001","title":"0.75 mg LY2189265","description":"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"BG002","title":"Exenatide","description":"Exenatide: 5 micrograms (mcg), subcutaneous (SC), twice daily for 4 weeks, followed by 10 mcg, SC, twice daily for 48 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"BG003","title":"Placebo","description":"Placebo: subcutaneous (SC), once weekly for 26 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 26 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 26 weeks"},{"id":"BG004","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"279"},{"groupId":"BG001","value":"280"},{"groupId":"BG002","value":"276"},{"groupId":"BG003","value":"141"},{"groupId":"BG004","value":"976"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"56.25","spread":"9.72"},{"groupId":"BG001","value":"55.79","spread":"9.45"},{"groupId":"BG002","value":"55.45","spread":"10.15"},{"groupId":"BG003","value":"54.56","spread":"10.01"},{"groupId":"BG004","value":"55.65","spread":"9.81"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"116"},{"groupId":"BG001","value":"112"},{"groupId":"BG002","value":"120"},{"groupId":"BG003","value":"58"},{"groupId":"BG004","value":"406"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"163"},{"groupId":"BG001","value":"168"},{"groupId":"BG002","value":"156"},{"groupId":"BG003","value":"83"},{"groupId":"BG004","value":"570"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"93"},{"groupId":"BG001","value":"102"},{"groupId":"BG002","value":"91"},{"groupId":"BG003","value":"45"},{"groupId":"BG004","value":"331"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"186"},{"groupId":"BG001","value":"178"},{"groupId":"BG002","value":"184"},{"groupId":"BG003","value":"96"},{"groupId":"BG004","value":"644"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"40"},{"groupId":"BG001","value":"37"},{"groupId":"BG002","value":"38"},{"groupId":"BG003","value":"20"},{"groupId":"BG004","value":"135"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"24"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"3"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"18"},{"groupId":"BG003","value":"10"},{"groupId":"BG004","value":"76"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"205"},{"groupId":"BG001","value":"207"},{"groupId":"BG002","value":"211"},{"groupId":"BG003","value":"103"},{"groupId":"BG004","value":"726"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"11"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"226"},{"groupId":"BG001","value":"226"},{"groupId":"BG002","value":"223"},{"groupId":"BG003","value":"113"},{"groupId":"BG004","value":"788"}]}]},{"title":"Mexico","categories":[{"measurements":[{"groupId":"BG000","value":"37"},{"groupId":"BG001","value":"36"},{"groupId":"BG002","value":"35"},{"groupId":"BG003","value":"19"},{"groupId":"BG004","value":"127"}]}]},{"title":"Argentina","categories":[{"measurements":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"18"},{"groupId":"BG003","value":"9"},{"groupId":"BG004","value":"61"}]}]}]},{"title":"Body Weight","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"kilograms","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"96.22","spread":"19.63"},{"groupId":"BG001","value":"95.53","spread":"20.56"},{"groupId":"BG002","value":"97.37","spread":"18.87"},{"groupId":"BG003","value":"94.12","spread":"19.28"},{"groupId":"BG004","value":"96.04","spread":"19.64"}]}]}]},{"title":"Body Mass Index (BMI)","description":"Body mass index is an estimate of body fat based on body weight divided by height squared.","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"kilograms per meter squared (kg/m^2)","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"33.09","spread":"5.33"},{"groupId":"BG001","value":"33.00","spread":"5.50"},{"groupId":"BG002","value":"33.54","spread":"5.36"},{"groupId":"BG003","value":"32.90","spread":"5.66"},{"groupId":"BG004","value":"33.16","spread":"5.43"}]}]}]},{"title":"Glycosylated Hemoglobin (HbA1c)","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"percentage of glycosylated hemoglobin","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"8.10","spread":"1.34"},{"groupId":"BG001","value":"8.05","spread":"1.24"},{"groupId":"BG002","value":"8.07","spread":"1.34"},{"groupId":"BG003","value":"8.06","spread":"1.31"},{"groupId":"BG004","value":"8.07","spread":"1.31"}]}]}]},{"title":"Duration of Diabetes","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"8.76","spread":"5.59"},{"groupId":"BG001","value":"8.78","spread":"5.47"},{"groupId":"BG002","value":"8.84","spread":"5.71"},{"groupId":"BG003","value":"8.60","spread":"5.78"},{"groupId":"BG004","value":"8.76","spread":"5.61"}]}]}]},{"title":"Fasting Serum Glucose","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"millimoles per liter (mmol/L)","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"9.00","spread":"3.09"},{"groupId":"BG001","value":"8.84","spread":"2.76"},{"groupId":"BG002","value":"9.11","spread":"3.04"},{"groupId":"BG003","value":"9.22","spread":"3.01"},{"groupId":"BG004","value":"9.02","spread":"2.97"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline to 26 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c)","description":"Least squares (LS) means were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline HbA1c as a covariate.","populationDescription":"Participants who were randomized and received at least 1 dose of LY2189265, Exenatide, or Placebo with evaluable HbA1c data. Only pre-rescue measurements were used. Last observation carried forward (LOCF) was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"percentage of glycosylated hemoglobin","timeFrame":"Baseline, 26 weeks","groups":[{"id":"OG000","title":"1.5 mg LY2189265","description":"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG001","title":"0.75 mg LY2189265","description":"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG002","title":"Exenatide","description":"Exenatide: 5 micrograms (mcg), subcutaneous (SC), twice daily for 4 weeks, followed by 10 mcg, SC, twice daily for 48 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG003","title":"Placebo","description":"Placebo: subcutaneous (SC), once weekly for 26 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 26 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 26 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"271"},{"groupId":"OG001","value":"269"},{"groupId":"OG002","value":"266"},{"groupId":"OG003","value":"119"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.51","spread":"0.06"},{"groupId":"OG001","value":"-1.30","spread":"0.06"},{"groupId":"OG002","value":"-0.99","spread":"0.06"},{"groupId":"OG003","value":"-0.46","spread":"0.08"}]}]}],"analyses":[{"groupIds":["OG000","OG003"],"groupDescription":"Superiority analysis.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"P-value is adjusted for multiplicity based on a tree-gatekeeping strategy. To determine significance, p-value is compared to the family-wise 1-sided Type I error of 0.025. The confidence interval is not adjusted for multiplicity.","statisticalMethod":"ANCOVA","paramType":"LS Mean Difference","paramValue":"-1.05","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.22","ciUpperLimit":"-0.88"},{"groupIds":["OG000","OG002"],"groupDescription":"Non-inferiority analysis.","testedNonInferiority":true,"nonInferiorityType":"NON_INFERIORITY_OR_EQUIVALENCE","nonInferiorityComment":"A non-inferiority margin of 0.4% was used.","pValue":"<0.0001","pValueComment":"P-value is adjusted for multiplicity, based on tree-gatekeeping strategy. To determine significance, p-value is compared to the family-wise 1-sided Type I error of 0.025. The confidence interval is not adjusted for multiplicity.","statisticalMethod":"ANCOVA","paramType":"LS Mean Difference","paramValue":"-0.52","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.66","ciUpperLimit":"-0.39"},{"groupIds":["OG001","OG003"],"groupDescription":"Superiority analysis.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"P-value is adjusted for multiplicity based on a tree-gatekeeping strategy. To determine significance, p-value is compared to the family-wise 1-sided Type I error of 0.025. The confidence interval is not adjusted for multiplicity.","statisticalMethod":"ANCOVA","paramType":"LS Mean Difference","paramValue":"-0.84","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.01","ciUpperLimit":"-0.67"},{"groupIds":["OG000","OG002"],"groupDescription":"Superiority analysis.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"P-value is adjusted for multiplicity based on a tree-gatekeeping strategy. To determine significance, p-value is compared to the family-wise 1-sided Type I error of 0.025. The confidence interval is not adjusted for multiplicity.","statisticalMethod":"ANCOVA","paramType":"LS Mean Difference","paramValue":"-0.52","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.66","ciUpperLimit":"-0.39"},{"groupIds":["OG001","OG002"],"groupDescription":"Non-inferiority analysis.","testedNonInferiority":true,"nonInferiorityType":"NON_INFERIORITY_OR_EQUIVALENCE","nonInferiorityComment":"A non-inferiority margin of 0.4% was used.","pValue":"<0.001","pValueComment":"P-value is adjusted for multiplicity, based on tree-gatekeeping strategy. To determine significance, p-value is compared to the family-wise 1-sided Type I error of 0.025. The confidence interval is not adjusted for multiplicity.","statisticalMethod":"ANCOVA","paramType":"LS Mean Difference","paramValue":"-0.31","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.44","ciUpperLimit":"-0.18"},{"groupIds":["OG001","OG002"],"groupDescription":"Superiority analysis.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"P-value is adjusted for multiplicity based on a tree-gatekeeping strategy. To determine significance, p-value is compared to the family-wise 1-sided Type I error of 0.025. The confidence interval is not adjusted for multiplicity.","statisticalMethod":"ANCOVA","paramType":"LS Mean Difference","paramValue":"-0.31","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.44","ciUpperLimit":"-0.18"}]},{"type":"SECONDARY","title":"Change From Baseline to 52 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c)","description":"Least squares (LS) means were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline HbA1c as a covariate.","populationDescription":"Participants who were randomized at baseline to LY2189265 or Exenatide and received at least 1 dose of study drug with evaluable HbA1c data. Only pre-rescue measurements were used. LOCF was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"percentage of glycosylated hemoglobin","timeFrame":"Baseline, 52 weeks","groups":[{"id":"OG000","title":"1.5 mg LY2189265","description":"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG001","title":"0.75 mg LY2189265","description":"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG002","title":"Exenatide","description":"Exenatide: 5 micrograms (mcg), subcutaneous (SC), twice daily for 4 weeks, followed by 10 mcg, SC, twice daily for 48 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"271"},{"groupId":"OG001","value":"269"},{"groupId":"OG002","value":"266"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.36","spread":"0.08"},{"groupId":"OG001","value":"-1.07","spread":"0.08"},{"groupId":"OG002","value":"-0.80","spread":"0.08"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"groupDescription":"Non-inferiority analysis.","testedNonInferiority":true,"nonInferiorityType":"NON_INFERIORITY_OR_EQUIVALENCE","nonInferiorityComment":"A non-inferiority margin of 0.4% was used.","pValue":"<0.001","pValueComment":"P-value is adjusted for multiplicity, based on tree-gatekeeping strategy. To determine significance, p-value is compared to the family-wise 1-sided Type I error of 0.025. The confidence interval is not adjusted for multiplicity.","statisticalMethod":"ANCOVA","paramType":"LS Mean Difference","paramValue":"-0.56","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.73","ciUpperLimit":"-0.39"},{"groupIds":["OG001","OG002"],"groupDescription":"Non-inferiority analysis.","testedNonInferiority":true,"nonInferiorityType":"NON_INFERIORITY_OR_EQUIVALENCE","nonInferiorityComment":"A non-inferiority margin of 0.4% was used.","pValue":"<0.001","pValueComment":"P-value is adjusted for multiplicity, based on tree-gatekeeping strategy. To determine significance, p-value is compared to the family-wise 1-sided Type I error of 0.025. The confidence interval is not adjusted for multiplicity.","statisticalMethod":"ANCOVA","paramType":"LS Mean Difference","paramValue":"-0.27","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.44","ciUpperLimit":"-0.11"},{"groupIds":["OG000","OG002"],"groupDescription":"Superiority analysis.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"P-value is adjusted for multiplicity based on a tree-gatekeeping strategy. To determine significance, p-value is compared to the family-wise 1-sided Type I error of 0.025. The confidence interval is not adjusted for multiplicity.","statisticalMethod":"ANCOVA","paramType":"LS Mean Difference","paramValue":"-0.56","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.73","ciUpperLimit":"-0.39"},{"groupIds":["OG001","OG002"],"groupDescription":"Superiority analysis.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"P-value is adjusted for multiplicity, based on tree-gatekeeping strategy. To determine significance, p-value is compared to the family-wise 1-sided Type I error of 0.025. The confidence interval is not adjusted for multiplicity.","statisticalMethod":"ANCOVA","paramType":"LS Mean Difference","paramValue":"-0.27","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.44","ciUpperLimit":"-0.11"}]},{"type":"SECONDARY","title":"Change From Baseline to 26 Weeks for Body Weight","description":"Least squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) analysis with treatment, country, visit, and treatment-by-visit as fixed effects and baseline as a covariate.","populationDescription":"Participants who were randomized and received at least 1 dose of LY2189265, Exenatide, or Placebo with evaluable body weight data. Only pre-rescue measurements were used.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"kilograms (kg)","timeFrame":"Baseline, 26 weeks","groups":[{"id":"OG000","title":"1.5 mg LY2189265","description":"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG001","title":"0.75 mg LY2189265","description":"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG002","title":"Exenatide","description":"Exenatide: 5 micrograms (mcg), subcutaneous (SC), twice daily for 4 weeks, followed by 10 mcg, SC, twice daily for 48 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG003","title":"Placebo","description":"Placebo: subcutaneous (SC), once weekly for 26 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 26 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 26 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"259"},{"groupId":"OG001","value":"253"},{"groupId":"OG002","value":"245"},{"groupId":"OG003","value":"109"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.34","spread":"0.25"},{"groupId":"OG001","value":"0.18","spread":"0.25"},{"groupId":"OG002","value":"-1.14","spread":"0.26"},{"groupId":"OG003","value":"1.37","spread":"0.37"}]}]}],"analyses":[{"groupIds":["OG000","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean Difference","paramValue":"-2.72","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-3.58","ciUpperLimit":"-1.85"},{"groupIds":["OG000","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.571","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean Difference","paramValue":"-0.20","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.88","ciUpperLimit":"0.49"},{"groupIds":["OG001","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.007","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean Difference","paramValue":"-1.19","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2.06","ciUpperLimit":"-0.33"},{"groupIds":["OG001","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean Difference","paramValue":"1.33","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.64","ciUpperLimit":"2.01"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean Difference","paramValue":"-2.52","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-3.39","ciUpperLimit":"-1.65"}]},{"type":"SECONDARY","title":"Change From Baseline to 52 Weeks for Body Weight","description":"Least squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) analysis with treatment, country, visit, and treatment-by-visit as fixed effects and baseline as a covariate.","populationDescription":"Participants who were randomized at baseline to LY2189265 or Exenatide and received at least 1 dose of study drug with evaluable body weight data. Only pre-rescue measurements were used.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"kilograms (kg)","timeFrame":"Baseline, 52 weeks","groups":[{"id":"OG000","title":"1.5 mg LY2189265","description":"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG001","title":"0.75 mg LY2189265","description":"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG002","title":"Exenatide","description":"Exenatide: 5 micrograms (mcg), subcutaneous (SC), twice daily for 4 weeks, followed by 10 mcg, SC, twice daily for 48 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"238"},{"groupId":"OG001","value":"231"},{"groupId":"OG002","value":"210"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.08","spread":"0.34"},{"groupId":"OG001","value":"0.49","spread":"0.34"},{"groupId":"OG002","value":"-0.76","spread":"0.35"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.507","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean Difference","paramValue":"-0.32","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.25","ciUpperLimit":"0.62"},{"groupIds":["OG001","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.009","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean Difference","paramValue":"1.25","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.32","ciUpperLimit":"2.19"}]},{"type":"SECONDARY","title":"Change From Baseline to 26 Weeks on Body Mass Index (BMI)","description":"Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.","populationDescription":"Participants who were randomized and received at least 1 dose of LY2189265, Exenatide, or Placebo with evaluable BMI data. Only pre-rescue measurements were used.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"kilograms per meter squared (kg/m^2)","timeFrame":"Baseline, 26 weeks","groups":[{"id":"OG000","title":"1.5 mg LY2189265","description":"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG001","title":"0.75 mg LY2189265","description":"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG002","title":"Exenatide","description":"Exenatide: 5 micrograms (mcg), subcutaneous (SC), twice daily for 4 weeks, followed by 10 mcg, SC, twice daily for 48 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG003","title":"Placebo","description":"Placebo: subcutaneous (SC), once weekly for 26 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 26 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 26 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"259"},{"groupId":"OG001","value":"253"},{"groupId":"OG002","value":"245"},{"groupId":"OG003","value":"109"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.48","spread":"0.09"},{"groupId":"OG001","value":"0.07","spread":"0.09"},{"groupId":"OG002","value":"-0.41","spread":"0.09"},{"groupId":"OG003","value":"0.49","spread":"0.13"}]}]}],"analyses":[{"groupIds":["OG000","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Means Difference","paramValue":"-0.97","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.27","ciUpperLimit":"-0.67"},{"groupIds":["OG000","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.568","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean Difference","paramValue":"-0.07","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.31","ciUpperLimit":"0.17"},{"groupIds":["OG001","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.006","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean Difference","paramValue":"-0.42","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.72","ciUpperLimit":"-0.12"},{"groupIds":["OG001","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean Difference","paramValue":"0.48","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.24","ciUpperLimit":"0.71"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean Difference","paramValue":"-0.90","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.20","ciUpperLimit":"-0.60"}]},{"type":"SECONDARY","title":"Change From Baseline to 52 Weeks on Body Mass Index (BMI)","description":"Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.","populationDescription":"Participants who were randomized at baseline to LY2189265 or Exenatide and received at least 1 dose of study drug with evaluable BMI data. Only pre-rescue measurements were used.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"kilograms per meter squared (kg/m^2)","timeFrame":"Baseline, 52 weeks","groups":[{"id":"OG000","title":"1.5 mg LY2189265","description":"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG001","title":"0.75 mg LY2189265","description":"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG002","title":"Exenatide","description":"Exenatide: 5 micrograms (mcg), subcutaneous (SC), twice daily for 4 weeks, followed by 10 mcg, SC, twice daily for 48 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"238"},{"groupId":"OG001","value":"231"},{"groupId":"OG002","value":"210"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.37","spread":"0.12"},{"groupId":"OG001","value":"0.18","spread":"0.12"},{"groupId":"OG002","value":"-0.28","spread":"0.12"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.580","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean Difference","paramValue":"-0.09","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.42","ciUpperLimit":"0.23"},{"groupIds":["OG001","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.005","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean Difference","paramValue":"0.46","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.14","ciUpperLimit":"0.79"}]},{"type":"SECONDARY","title":"Change From Baseline to 26 Weeks for Daily Mean Blood Glucose Values From the 8-point Self-monitored Plasma Glucose (SMPG) Profiles","description":"The SMPG data were collected at the following 8 time points: pre-morning meal; 2 hours post-morning meal; pre-midday meal; 2 hours post-midday meal; pre-evening; 2 hours post-evening meal; bedtime; and 3AM or 5 hours after bedtime. Least squares (LS) means of the mean of the 8 time points (daily mean) were calculated using a mixed-effects model for repeated measures (MMRM) analysis with treatment, country, visit, and treatment-by-visit as fixed effects and baseline as a covariate.","populationDescription":"Participants who were randomized and received at least 1 dose of LY2189265, Exenatide, or Placebo with evaluable SMPG data. Only pre-rescue measurements were used.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"milligrams per deciliter (mg/dL)","timeFrame":"Baseline, 26 weeks","groups":[{"id":"OG000","title":"1.5 mg LY2189265","description":"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG001","title":"0.75 mg LY2189265","description":"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG002","title":"Exenatide","description":"Exenatide: 5 micrograms (mcg), subcutaneous (SC), twice daily for 4 weeks, followed by 10 mcg, SC, twice daily for 48 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG003","title":"Placebo","description":"Placebo: subcutaneous (SC), once weekly for 26 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 26 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 26 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"207"},{"groupId":"OG001","value":"195"},{"groupId":"OG002","value":"202"},{"groupId":"OG003","value":"78"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-46.82","spread":"1.81"},{"groupId":"OG001","value":"-42.09","spread":"1.87"},{"groupId":"OG002","value":"-37.48","spread":"1.83"},{"groupId":"OG003","value":"-18.07","spread":"2.68"}]}]}],"analyses":[{"groupIds":["OG000","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean Difference","paramValue":"-28.76","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-34.50","ciUpperLimit":"-23.02"},{"groupIds":["OG000","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean Difference","paramValue":"-9.34","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-13.62","ciUpperLimit":"-5.06"},{"groupIds":["OG001","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean Difference","paramValue":"-24.02","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-29.80","ciUpperLimit":"-18.24"},{"groupIds":["OG001","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.038","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean Difference","paramValue":"-4.61","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-8.95","ciUpperLimit":"-0.27"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean Difference","paramValue":"-19.41","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-25.18","ciUpperLimit":"-13.65"}]},{"type":"SECONDARY","title":"Change From Baseline to 52 Weeks for Daily Mean Blood Glucose Values From the 8-point Self-monitored Plasma Glucose (SMPG) Profiles","description":"The SMPG data were collected at the following 8 time points: pre-morning meal; 2 hours post-morning meal; pre-midday meal; 2 hours post-midday meal; pre-evening; 2 hours post-evening meal; bedtime; and 3AM or 5 hours after bedtime. Least squares (LS) means of the mean of the 8 time points (daily mean) were calculated using a mixed-effects model for repeated measures (MMRM) analysis with treatment, country, visit, and treatment-by-visit as fixed effects and baseline as a covariate.","populationDescription":"Participants who were randomized at baseline to LY2189265 or Exenatide and received at least 1 dose of study drug with evaluable SMPG data. Only pre-rescue measurements were used.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"milligrams per deciliter (mg/dL)","timeFrame":"Baseline, 52 weeks","groups":[{"id":"OG000","title":"1.5 mg LY2189265","description":"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG001","title":"0.75 mg LY2189265","description":"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG002","title":"Exenatide","description":"Exenatide: 5 micrograms (mcg), subcutaneous (SC), twice daily for 4 weeks, followed by 10 mcg, SC, twice daily for 48 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"187"},{"groupId":"OG001","value":"185"},{"groupId":"OG002","value":"178"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-43.84","spread":"2.07"},{"groupId":"OG001","value":"-40.62","spread":"2.12"},{"groupId":"OG002","value":"-36.16","spread":"2.11"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.004","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean Difference","paramValue":"-7.68","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-12.84","ciUpperLimit":"-2.52"},{"groupIds":["OG001","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.092","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean Difference","paramValue":"-4.47","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-9.66","ciUpperLimit":"0.73"}]},{"type":"SECONDARY","title":"Percentage of Participants Attaining Glycosylated Hemoglobin (HbA1c) Less Than 7% and Less Than or Equal to 6.5% at 26 Weeks","description":"The percentage of participants achieving HbA1c level less than 7.0% and less than or equal to 6.5% was analyzed with a logistic regression model with baseline, country, and treatment as factors included in the model.","populationDescription":"Participants who were randomized and received at least 1 dose of LY2189265, Exenatide, or Placebo with evaluable HbA1c data. Only pre-rescue measurements were used. Last observation carried forward (LOCF) was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Baseline, 26 weeks","groups":[{"id":"OG000","title":"1.5 mg LY2189265","description":"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG001","title":"0.75 mg LY2189265","description":"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG002","title":"Exenatide","description":"Exenatide: 5 micrograms (mcg), subcutaneous (SC), twice daily for 4 weeks, followed by 10 mcg, SC, twice daily for 48 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG003","title":"Placebo","description":"Placebo: subcutaneous (SC), once weekly for 26 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 26 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 26 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"271"},{"groupId":"OG001","value":"269"},{"groupId":"OG002","value":"266"},{"groupId":"OG003","value":"119"}]}],"classes":[{"title":"HbA1c Less Than 7%","categories":[{"measurements":[{"groupId":"OG000","value":"78.2"},{"groupId":"OG001","value":"65.8"},{"groupId":"OG002","value":"52.3"},{"groupId":"OG003","value":"42.9"}]}]},{"title":"HbA1c Less Than or Equal to 6.5%","categories":[{"measurements":[{"groupId":"OG000","value":"62.7"},{"groupId":"OG001","value":"53.2"},{"groupId":"OG002","value":"38.0"},{"groupId":"OG003","value":"24.4"}]}]}],"analyses":[{"groupIds":["OG000","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"Treatment comparison for HbA1c less than 7.0%.","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"13.1","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"7.4","ciUpperLimit":"23.4"},{"groupIds":["OG000","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"Treatment comparison for HbA1c less than 7.0%.","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"6.2","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"3.9","ciUpperLimit":"10.1"},{"groupIds":["OG001","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"Treatment comparison for HbA1c less than 7.0%.","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"4.8","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"2.8","ciUpperLimit":"8.0"},{"groupIds":["OG001","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"Treatment comparison for HbA1c less than 7.0%.","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"2.3","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.5","ciUpperLimit":"3.5"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.004","pValueComment":"Treatment comparison for HbA1c less than 7.0%.","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"2.1","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.3","ciUpperLimit":"3.5"},{"groupIds":["OG000","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"Treatment comparison for HbA1c less than or equal to 6.5%.","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"11.8","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"6.7","ciUpperLimit":"20.8"},{"groupIds":["OG000","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"Treatment comparison for HbA1c less than or equal to 6.5%.","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"4.4","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"2.9","ciUpperLimit":"6.8"},{"groupIds":["OG001","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"Treatment comparison for HbA1c less than or equal to 6.5%.","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"6.3","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"3.7","ciUpperLimit":"10.9"},{"groupIds":["OG001","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"Treatment comparison for HbA1c less than or equal to 6.5%.","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"2.4","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.6","ciUpperLimit":"3.5"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"Treatment comparison for HbA1c less than or equal to 6.5%.","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"2.7","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.6","ciUpperLimit":"4.6"}]},{"type":"SECONDARY","title":"Percentage of Participants Attaining Glycosylated Hemoglobin (HbA1c) Less Than 7% and Less Than or Equal to 6.5% at 52 Weeks","description":"The percentage of participants achieving HbA1c level less than 7.0% and less than or equal to 6.5% was analyzed with a logistic regression model with baseline, country, and treatment as factors included in the model.","populationDescription":"Participants who were randomized at baseline to LY2189265 or Exenatide and received at least 1 dose of study drug with evaluable HbA1c data. Only pre-rescue measurements were used. LOCF was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Baseline, 52 weeks","groups":[{"id":"OG000","title":"1.5 mg LY2189265","description":"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG001","title":"0.75 mg LY2189265","description":"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG002","title":"Exenatide","description":"Exenatide: 5 micrograms (mcg), subcutaneous (SC), twice daily for 4 weeks, followed by 10 mcg, SC, twice daily for 48 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"271"},{"groupId":"OG001","value":"269"},{"groupId":"OG002","value":"266"}]}],"classes":[{"title":"HbA1c Less Than 7.0%","categories":[{"measurements":[{"groupId":"OG000","value":"70.8"},{"groupId":"OG001","value":"59.1"},{"groupId":"OG002","value":"49.2"}]}]},{"title":"HbA1c Less Than or Equal to 6.5%","categories":[{"measurements":[{"groupId":"OG000","value":"57.2"},{"groupId":"OG001","value":"48.3"},{"groupId":"OG002","value":"34.6"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"Treatment comparison for HbA1c less than 7.0%.","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"3.7","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"2.4","ciUpperLimit":"5.6"},{"groupIds":["OG001","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.008","pValueComment":"Treatment comparison for HbA1c less than 7.0%.","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"1.7","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.1","ciUpperLimit":"2.5"},{"groupIds":["OG000","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"Treatment comparison for HbA1c less than or equal to 6.5%.","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"3.5","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"2.3","ciUpperLimit":"5.1"},{"groupIds":["OG001","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"Treatment comparison for HbA1c less than or equal to 6.5%.","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"2.1","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.4","ciUpperLimit":"3.1"}]},{"type":"SECONDARY","title":"Change From Baseline to 26 Weeks in Updated Homeostasis Model Assessment of Beta-cell Function (HOMA2-%B) and Updated Homeostasis Model Assessment of Insulin Sensitivity (HOMA2-%S)","description":"The homeostatic model assessment (HOMA) quantifies insulin resistance and beta-cell function. HOMA2-B is a computer model that uses fasting plasma insulin and glucose concentrations to estimate steady-state beta cell function (%B) as a percentage of a normal reference population (normal young adults). HOMA2-S is a computer model that uses fasting plasma insulin and glucose concentrations to estimate insulin sensitivity (%S) as percentages of a normal reference population (normal young adults). The normal reference populations were set at 100%. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.","populationDescription":"Participants who were randomized and received at least 1 dose of LY2189265, Exenatide, or Placebo with evaluable HOMA2-%B or HOMA2-%S data. Only pre-rescue measurements were used.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"percentage of HOMA2","timeFrame":"Baseline, 26 weeks","groups":[{"id":"OG000","title":"1.5 mg LY2189265","description":"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG001","title":"0.75 mg LY2189265","description":"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG002","title":"Exenatide","description":"Exenatide: 5 micrograms (mcg), subcutaneous (SC), twice daily for 4 weeks, followed by 10 mcg, SC, twice daily for 48 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG003","title":"Placebo","description":"Placebo: subcutaneous (SC), once weekly for 26 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 26 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 26 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"238"},{"groupId":"OG001","value":"218"},{"groupId":"OG002","value":"223"},{"groupId":"OG003","value":"98"}]}],"classes":[{"title":"HOMA2-%B","categories":[{"measurements":[{"groupId":"OG000","value":"36.14","spread":"2.60"},{"groupId":"OG001","value":"23.61","spread":"2.67"},{"groupId":"OG002","value":"15.02","spread":"2.62"},{"groupId":"OG003","value":"0.93","spread":"3.66"}]}]},{"title":"HOMA2-%S","categories":[{"measurements":[{"groupId":"OG000","value":"-3.14","spread":"2.91"},{"groupId":"OG001","value":"1.16","spread":"2.97"},{"groupId":"OG002","value":"-1.59","spread":"2.92"},{"groupId":"OG003","value":"2.56","spread":"4.07"}]}]}],"analyses":[{"groupIds":["OG000","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"Treatment comparison of HOMA2-B","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean Difference","paramValue":"35.21","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"27.26","ciUpperLimit":"43.16"},{"groupIds":["OG000","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"Treatment comparison of HOMA2-B","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean Difference","paramValue":"21.12","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"14.97","ciUpperLimit":"27.28"},{"groupIds":["OG001","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"Treatment comparison of HOMA2-B","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean Difference","paramValue":"22.68","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"14.63","ciUpperLimit":"30.72"},{"groupIds":["OG001","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.007","pValueComment":"Treatment comparison of HOMA2-B","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean Difference","paramValue":"8.59","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"2.31","ciUpperLimit":"14.87"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"Treatment comparison of HOMA2-B","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean Difference","paramValue":"14.09","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"6.06","ciUpperLimit":"22.11"},{"groupIds":["OG000","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.207","pValueComment":"Treatment comparison of HOMA2-S","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean Difference","paramValue":"-5.70","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-14.56","ciUpperLimit":"3.17"},{"groupIds":["OG000","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.659","pValueComment":"Treatment comparison of HOMA2-S","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean Difference","paramValue":"-1.54","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-8.41","ciUpperLimit":"5.32"},{"groupIds":["OG001","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.759","pValueComment":"Treatment comparison of HOMA2-S","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean Difference","paramValue":"-1.40","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-10.37","ciUpperLimit":"7.56"},{"groupIds":["OG001","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.441","pValueComment":"Treatment comparison of HOMA2-S","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean Difference","paramValue":"2.75","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-4.25","ciUpperLimit":"9.76"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.362","pValueComment":"Treatment comparison of HOMA2-S","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean Difference","paramValue":"-4.15","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-13.10","ciUpperLimit":"4.79"}]},{"type":"SECONDARY","title":"Change From Baseline to 52 Weeks in Updated Homeostasis Model Assessment of Beta-cell Function (HOMA2-%B) and Updated Homeostasis Model Assessment of Insulin Sensitivity (HOMA2-%S)","description":"The homeostatic model assessment (HOMA) quantifies insulin resistance and beta-cell function. HOMA2-B is a computer model that uses fasting plasma insulin and glucose concentrations to estimate steady-state beta cell function (%B) as a percentage of a normal reference population (normal young adults). HOMA2-S is a computer model that uses fasting plasma insulin and glucose concentrations to estimate insulin sensitivity (%S) as percentages of a normal reference population (normal young adults). The normal reference populations were set at 100%. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.","populationDescription":"Participants who were randomized at baseline to LY2189265 or Exenatide and received at least 1 dose of study drug with evaluable HOMA2-%B or HOMA2-%S data. Only pre-rescue measurements were used.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"percentage of HOMA2","timeFrame":"Baseline, 52 weeks","groups":[{"id":"OG000","title":"1.5 mg LY2189265","description":"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG001","title":"0.75 mg LY2189265","description":"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG002","title":"Exenatide","description":"Exenatide: 5 micrograms (mcg), subcutaneous (SC), twice daily for 4 weeks, followed by 10 mcg, SC, twice daily for 48 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"219"},{"groupId":"OG001","value":"202"},{"groupId":"OG002","value":"187"}]}],"classes":[{"title":"HOMA2-%B","categories":[{"measurements":[{"groupId":"OG000","value":"35.21","spread":"2.63"},{"groupId":"OG001","value":"25.69","spread":"2.70"},{"groupId":"OG002","value":"13.57","spread":"2.75"}]}]},{"title":"HOMA2-%S","categories":[{"measurements":[{"groupId":"OG000","value":"-7.48","spread":"2.93"},{"groupId":"OG001","value":"-5.49","spread":"3.01"},{"groupId":"OG002","value":"-3.75","spread":"3.07"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"Treatment comparison of HOMA2-B","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean Difference","paramValue":"21.64","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"15.20","ciUpperLimit":"28.08"},{"groupIds":["OG001","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"Treatment comparison of HOMA2-B","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean Difference","paramValue":"12.12","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"5.56","ciUpperLimit":"18.68"},{"groupIds":["OG000","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.307","pValueComment":"Treatment comparison of HOMA2-S","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean Difference","paramValue":"-3.73","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-10.90","ciUpperLimit":"3.43"},{"groupIds":["OG001","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.638","pValueComment":"Treatment comparison of HOMA2-S","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean Difference","paramValue":"-1.75","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-9.05","ciUpperLimit":"5.55"}]},{"type":"SECONDARY","title":"Change From Baseline to 26 Weeks in the EuroQol 5","description":"The European Quality of Life - 5 dimensions (EQ-5D) questionnaire is a generic, multidimensional, health-related, quality-of-life instrument. It consists of 2 parts: the first part assesses 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) that have 3 possible levels of response (no problem, some problem, or extreme problem). These dimensions are converted into a weighted health-state Index Score. The EQ-5D United Kingdom (UK) score ranges from -0.59 to 1.0, where a score of 1.0 indicates perfect health and negative values are valued as worse than dead. The second part of the questionnaire consists of a visual analog scale (VAS) on which the participants rated their perceived health state on that day from 0 (worst imaginable health state) to 100 (best imaginable health). Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) and adjusted by treatment, country, and baseline.","populationDescription":"Participants who were randomized and received at least 1 dose of LY2189265, Exenatide, or Placebo with evaluable EQ-5D data. Only pre-rescue measurements were used. Last observation carried forward (LOCF) was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Baseline, 26 weeks","groups":[{"id":"OG000","title":"1.5 mg LY2189265","description":"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG001","title":"0.75 mg LY2189265","description":"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG002","title":"Exenatide","description":"Exenatide: 5 micrograms (mcg), subcutaneous (SC), twice daily for 4 weeks, followed by 10 mcg, SC, twice daily for 48 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG003","title":"Placebo","description":"Placebo: subcutaneous (SC), once weekly for 26 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 26 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 26 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"279"},{"groupId":"OG001","value":"280"},{"groupId":"OG002","value":"276"},{"groupId":"OG003","value":"141"}]}],"classes":[{"title":"VAS Health State Score (n=270, 267, 264, 119)","categories":[{"measurements":[{"groupId":"OG000","value":"4.50","spread":"0.85"},{"groupId":"OG001","value":"2.41","spread":"0.85"},{"groupId":"OG002","value":"3.94","spread":"0.85"},{"groupId":"OG003","value":"0.71","spread":"1.15"}]}]},{"title":"EQ-5D UK (n=270, 266, 264, 119)","categories":[{"measurements":[{"groupId":"OG000","value":"0.01","spread":"0.01"},{"groupId":"OG001","value":"0.01","spread":"0.01"},{"groupId":"OG002","value":"0.00","spread":"0.01"},{"groupId":"OG003","value":"-0.00","spread":"0.02"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to 52 Weeks in the EuroQol 5","description":"The European Quality of Life - 5 dimensions (EQ-5D) questionnaire is a generic, multidimensional, health-related, quality-of-life instrument. It consists of 2 parts: the first part assesses 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) that have 3 possible levels of response (no problem, some problem, or extreme problem). These dimensions are converted into a weighted health-state Index Score. The EQ-5D United Kingdom (UK) score ranges from -0.59 to 1.0, where a score of 1.0 indicates perfect health and negative values are valued as worse than dead. The second part of the questionnaire consists of a visual analog scale (VAS) on which the participants rated their perceived health state on that day from 0 (worst imaginable health state) to 100 (best imaginable health). Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) and adjusted by treatment, country, and baseline.","populationDescription":"Participants who were randomized at baseline to LY2189265 or Exenatide and received at least 1 dose of study drug with evaluable EQ-5D data. Only pre-rescue measurements were used. LOCF was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Baseline, 52 weeks","groups":[{"id":"OG000","title":"1.5 mg LY2189265","description":"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG001","title":"0.75 mg LY2189265","description":"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG002","title":"Exenatide","description":"Exenatide: 5 micrograms (mcg), subcutaneous (SC), twice daily for 4 weeks, followed by 10 mcg, SC, twice daily for 48 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"279"},{"groupId":"OG001","value":"280"},{"groupId":"OG002","value":"276"}]}],"classes":[{"title":"VAS Health State Score (n=270, 267, 264)","categories":[{"measurements":[{"groupId":"OG000","value":"5.15","spread":"0.89"},{"groupId":"OG001","value":"3.52","spread":"0.89"},{"groupId":"OG002","value":"3.51","spread":"0.89"}]}]},{"title":"EQ-5D UK (n=270, 266, 264)","categories":[{"measurements":[{"groupId":"OG000","value":"0.02","spread":"0.01"},{"groupId":"OG001","value":"0.01","spread":"0.01"},{"groupId":"OG002","value":"-0.00","spread":"0.01"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to 26 Weeks in the Diabetes Treatment Satisfaction Questionnaire Status (DTSQs) Version","description":"The Diabetes Treatment Satisfaction Questionnaire status version (DTSQs) is used to assess participant treatment satisfaction at each study visit. The questionnaire consists of 8 items, 6 of which (1, and 4 through 8) assess treatment satisfaction. Each item is rated on a 7-point Likert scale. Scores from the 6 treatment satisfaction items are summed to a Total Treatment Satisfaction Score, which ranges from 0 (very dissatisfied) to 36 (very satisfied). The DTSQ change version (DTSQc) was not collected at 26 weeks. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline score as a covariate.","populationDescription":"Participants who were randomized and received at least 1 dose of LY2189265, Exenatide, or Placebo with evaluable DTSQs data. Only pre-rescue measurements were used. Last observation carried forward (LOCF) used to impute missing postbaseline values. If there were no data after randomization, endpoint was considered missing.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Baseline, 26 weeks","groups":[{"id":"OG000","title":"1.5 mg LY2189265","description":"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG001","title":"0.75 mg LY2189265","description":"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG002","title":"Exenatide","description":"Exenatide: 5 micrograms (mcg), subcutaneous (SC), twice daily for 4 weeks, followed by 10 mcg, SC, twice daily for 48 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG003","title":"Placebo","description":"Placebo: subcutaneous (SC), once weekly for 26 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 26 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 26 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"270"},{"groupId":"OG001","value":"268"},{"groupId":"OG002","value":"266"},{"groupId":"OG003","value":"119"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.40","spread":"0.34"},{"groupId":"OG001","value":"2.56","spread":"0.33"},{"groupId":"OG002","value":"0.85","spread":"0.33"},{"groupId":"OG003","value":"0.49","spread":"0.45"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to 52 Weeks in the Diabetes Treatment Satisfaction Questionnaire Status (DTSQs) and Change (DTSQc) Versions","description":"The Diabetes Treatment Satisfaction Questionnaire status (DTSQs) and change (DTSQc) versions are used to assess participant treatment satisfaction at each study visit and relative change in satisfaction from baseline, respectively. Both questionnaires consist of 8 items, 6 of which (1, and 4 through 8) assess treatment satisfaction. Each item is rated on a 7-point Likert scale. The change version has the same 8 items as the status version with a small alteration of the wording of Item 7. Scores from the 6 treatment satisfaction items are summed to a Total Treatment Satisfaction Score, which ranges from 0 (very dissatisfied) to 36 (very satisfied) for the DTSQs and from -18 (much less satisfied) to +18 (much more satisfied) for the DTSQc. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline score as a covariate.","populationDescription":"Participants who were randomized at baseline to LY2189265 or Exenatide and received at least 1 dose of study drug with evaluable DTSQs or DTSQc data. Only pre-rescue measurements were used. LOCF was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Baseline, 52 weeks","groups":[{"id":"OG000","title":"1.5 mg LY2189265","description":"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG001","title":"0.75 mg LY2189265","description":"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG002","title":"Exenatide","description":"Exenatide: 5 micrograms (mcg), subcutaneous (SC), twice daily for 4 weeks, followed by 10 mcg, SC, twice daily for 48 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"279"},{"groupId":"OG001","value":"280"},{"groupId":"OG002","value":"276"}]}],"classes":[{"title":"DTSQs Treatment Satisfaction (n=270, 268, 266)","categories":[{"measurements":[{"groupId":"OG000","value":"2.05","spread":"0.36"},{"groupId":"OG001","value":"2.11","spread":"0.36"},{"groupId":"OG002","value":"0.69","spread":"0.36"}]}]},{"title":"DTSQc Treatment Satisfaction (n=249, 237, 226)","categories":[{"measurements":[{"groupId":"OG000","value":"15.36","spread":"0.40"},{"groupId":"OG001","value":"15.46","spread":"0.41"},{"groupId":"OG002","value":"14.01","spread":"0.41"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to 26 Weeks in the Impact of Weight on Activities of Daily Living","description":"The Impact of Weight on Activities of Daily Living (renamed the Ability to Perform Physical Activities of Daily Living \\[APPADL\\]) questionnaire contains 7 items that assess how difficult it is for participants to engage in certain activities considered to be integral to normal daily life, such as walking, standing and climbing stairs. Items are scored on a 5-point numeric rating scale where 5 = \"not at all difficult\" and 1 = \"unable to do\". The individual scores from all 7 items are summed and a single total score is calculated and may range between 7 and 35. A higher score indicates better ability to perform activities of daily living. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline as a covariate.","populationDescription":"Participants who were randomized and received at least 1 dose of LY2189265, Exenatide, or Placebo with evaluable APPADL data. Only pre-rescue measurements were used. Last observation carried forward (LOCF) was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Baseline, 26 weeks","groups":[{"id":"OG000","title":"1.5 mg LY2189265","description":"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG001","title":"0.75 mg LY2189265","description":"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG002","title":"Exenatide","description":"Exenatide: 5 micrograms (mcg), subcutaneous (SC), twice daily for 4 weeks, followed by 10 mcg, SC, twice daily for 48 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG003","title":"Placebo","description":"Placebo: subcutaneous (SC), once weekly for 26 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 26 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 26 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"270"},{"groupId":"OG001","value":"267"},{"groupId":"OG002","value":"266"},{"groupId":"OG003","value":"119"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.18","spread":"0.27"},{"groupId":"OG001","value":"0.12","spread":"0.27"},{"groupId":"OG002","value":"0.47","spread":"0.27"},{"groupId":"OG003","value":"0.03","spread":"0.36"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to 52 Weeks in the Impact of Weight on Activities of Daily Living","description":"The Impact of Weight on Activities of Daily Living (renamed the Ability to Perform Physical Activities of Daily Living \\[APPADL\\]) questionnaire contains 7 items that assess how difficult it is for participants to engage in certain activities considered to be integral to normal daily life, such as walking, standing and climbing stairs. Items are scored on a 5-point numeric rating scale where 5 = \"not at all difficult\" and 1 = \"unable to do\". The individual scores from all 7 items are summed and a single total score is calculated and may range between 7 and 35. A higher score indicates better ability to perform activities of daily living. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline as a covariate.","populationDescription":"Participants who were randomized at baseline to LY2189265 or Exenatide and received at least 1 dose of study drug with evaluable APPADL data. Only pre-rescue measurements were used. LOCF was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Baseline, 52 weeks","groups":[{"id":"OG000","title":"1.5 mg LY2189265","description":"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG001","title":"0.75 mg LY2189265","description":"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG002","title":"Exenatide","description":"Exenatide: 5 micrograms (mcg), subcutaneous (SC), twice daily for 4 weeks, followed by 10 mcg, SC, twice daily for 48 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"270"},{"groupId":"OG001","value":"267"},{"groupId":"OG002","value":"266"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.18","spread":"0.29"},{"groupId":"OG001","value":"-0.18","spread":"0.29"},{"groupId":"OG002","value":"0.35","spread":"0.29"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to 26 Weeks on the Impact of Weight on Self-Perception","description":"The Impact of Weight on Self-Perception (IW-SP) questionnaire contains 3 items that assess how often the participants' body weight affects how happy they are with their appearance and how often they feel self-conscious when out in public. Items are scored on a 5-point numeric rating scale where 5 = never and 1 = always. A single total score is calculated by summing the scores for all 3 items. Total score ranges between 3 and 15, where a higher score is indicative of better self-perception. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline as a covariate.","populationDescription":"Participants who were randomized and received at least 1 dose of LY2189265, Exenatide, or Placebo with evaluable IW-SP data. Only pre-rescue measurements were used. Last observation carried forward (LOCF) was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Baseline, 26 weeks","groups":[{"id":"OG000","title":"1.5 mg LY2189265","description":"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG001","title":"0.75 mg LY2189265","description":"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG002","title":"Exenatide","description":"Exenatide: 5 micrograms (mcg), subcutaneous (SC), twice daily for 4 weeks, followed by 10 mcg, SC, twice daily for 48 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG003","title":"Placebo","description":"Placebo: subcutaneous (SC), once weekly for 26 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 26 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 26 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"270"},{"groupId":"OG001","value":"267"},{"groupId":"OG002","value":"266"},{"groupId":"OG003","value":"119"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.56","spread":"0.15"},{"groupId":"OG001","value":"0.47","spread":"0.15"},{"groupId":"OG002","value":"0.46","spread":"0.15"},{"groupId":"OG003","value":"0.45","spread":"0.20"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to 52 Weeks on the Impact of Weight on Self-Perception","description":"The Impact of Weight on Self-Perception (IW-SP) questionnaire contains 3 items that assess how often the participants' body weight affects how happy they are with their appearance and how often they feel self-conscious when out in public. Items are scored on a 5-point numeric rating scale where 5 = never and 1 = always. A single total score is calculated by summing the scores for all 3 items. Total score ranges between 3 and 15, where a higher score is indicative of better self-perception. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline as a covariate.","populationDescription":"Participants who were randomized at baseline to LY2189265 or Exenatide and received at least 1 dose of study drug with evaluable IW-SP data. Only pre-rescue measurements were used. LOCF was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Baseline, 52 weeks","groups":[{"id":"OG000","title":"1.5 mg LY2189265","description":"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG001","title":"0.75 mg LY2189265","description":"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG002","title":"Exenatide","description":"Exenatide: 5 micrograms (mcg), subcutaneous (SC), twice daily for 4 weeks, followed by 10 mcg, SC, twice daily for 48 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"270"},{"groupId":"OG001","value":"267"},{"groupId":"OG002","value":"266"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":"0.15"},{"groupId":"OG001","value":"0.47","spread":"0.15"},{"groupId":"OG002","value":"0.64","spread":"0.15"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Adjudicated Cardiovascular Events at 52 Weeks","description":"Information on cardiovascular (CV) risk factors was collected at baseline. Data on any new CV event was prospectively collected using a CV event electronic case report form. At prespecified visits, participants were asked about any new CV event since the previous inquiry. Deaths and nonfatal cardiovascular adverse events (AEs) were adjudicated by an external committee of physicians with cardiology expertise. Nonfatal cardiovascular AEs to be adjudicated included myocardial infarction, hospitalization for unstable angina, hospitalization for heart failure, coronary interventions, and cerebrovascular events, including cerebrovascular accident (stroke) and transient ischemic attack. The number of participants with CV events confirmed by adjudication is summarized cumulatively at 52 weeks. Serious and all other non-serious adverse events regardless of causality are summarized in the Reported Adverse Events module.","populationDescription":"Participants who were randomized at baseline to LY2189265 or Exenatide and received at least 1 dose of study drug. The number of participants with adjudicated CV events was not collected at 26 weeks.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Baseline through 52 weeks","groups":[{"id":"OG000","title":"1.5 mg LY2189265","description":"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG001","title":"0.75 mg LY2189265","description":"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG002","title":"Exenatide","description":"Exenatide: 5 micrograms (mcg), subcutaneous (SC), twice daily for 4 weeks, followed by 10 mcg, SC, twice daily for 48 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"279"},{"groupId":"OG001","value":"280"},{"groupId":"OG002","value":"276"}]}],"classes":[{"title":"Any CV Event","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"}]}]},{"title":"Any Fatal Event","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any Non-fatal CV Event","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to 26 Weeks on Electrocardiogram Parameters, Fridericia Corrected QT (QTcF) Interval and PR Interval","description":"The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTc = QT/RR\\^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. PR is the interval between the P wave and the QRS complex. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.","populationDescription":"Participants who were randomized and received at least 1 dose of LY2189265, Exenatide, or Placebo with evaluable ECG QTcF Interval or PR interval data.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"milliseconds (msec)","timeFrame":"Baseline, 26 weeks","groups":[{"id":"OG000","title":"1.5 mg LY2189265","description":"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG001","title":"0.75 mg LY2189265","description":"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG002","title":"Exenatide","description":"Exenatide: 5 micrograms (mcg), subcutaneous (SC), twice daily for 4 weeks, followed by 10 mcg, SC, twice daily for 48 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG003","title":"Placebo","description":"Placebo: subcutaneous (SC), once weekly for 26 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 26 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 26 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"279"},{"groupId":"OG001","value":"280"},{"groupId":"OG002","value":"276"},{"groupId":"OG003","value":"141"}]}],"classes":[{"title":"QTcF Interval (n=253, 260, 250, 120)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.11","spread":"1.00"},{"groupId":"OG001","value":"0.91","spread":"0.99"},{"groupId":"OG002","value":"1.21","spread":"1.00"},{"groupId":"OG003","value":"1.32","spread":"1.33"}]}]},{"title":"PR Interval (n=252, 259, 246, 116)","categories":[{"measurements":[{"groupId":"OG000","value":"2.35","spread":"0.89"},{"groupId":"OG001","value":"0.93","spread":"0.88"},{"groupId":"OG002","value":"1.01","spread":"0.89"},{"groupId":"OG003","value":"-1.83","spread":"1.20"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to 52 Weeks on Electrocardiogram Parameters, Fridericia Corrected QT (QTcF) Interval and PR Interval","description":"The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTc = QT/RR\\^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. PR is the interval between the P wave and the QRS complex. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.","populationDescription":"Participants who were randomized at baseline to LY2189265 or Exenatide and received at least 1 dose of study drug with evaluable ECG QTcF Interval or PR Interval data.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"milliseconds (msec)","timeFrame":"Baseline, 52 weeks","groups":[{"id":"OG000","title":"1.5 mg LY2189265","description":"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG001","title":"0.75 mg LY2189265","description":"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG002","title":"Exenatide","description":"Exenatide: 5 micrograms (mcg), subcutaneous (SC), twice daily for 4 weeks, followed by 10 mcg, SC, twice daily for 48 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"279"},{"groupId":"OG001","value":"280"},{"groupId":"OG002","value":"276"}]}],"classes":[{"title":"QTcF Interval (n=239, 243, 226)","categories":[{"measurements":[{"groupId":"OG000","value":"1.28","spread":"1.07"},{"groupId":"OG001","value":"2.30","spread":"1.07"},{"groupId":"OG002","value":"2.52","spread":"1.10"}]}]},{"title":"PR Interval (n=237, 243, 220)","categories":[{"measurements":[{"groupId":"OG000","value":"2.57","spread":"0.96"},{"groupId":"OG001","value":"0.69","spread":"0.96"},{"groupId":"OG002","value":"-0.82","spread":"0.99"}]}]}]},{"type":"SECONDARY","title":"Change in Baseline to 26 Weeks on Pulse Rate","description":"Seated pulse rate was measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.","populationDescription":"Participants who were randomized and received at least 1 dose of LY2189265, Exenatide, or Placebo with evaluable seated pulse rate data.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"beats per minute (bpm)","timeFrame":"Baseline, 26 weeks","groups":[{"id":"OG000","title":"1.5 mg LY2189265","description":"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG001","title":"0.75 mg LY2189265","description":"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG002","title":"Exenatide","description":"Exenatide: 5 micrograms (mcg), subcutaneous (SC), twice daily for 4 weeks, followed by 10 mcg, SC, twice daily for 48 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG003","title":"Placebo","description":"Placebo: subcutaneous (SC), once weekly for 26 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 26 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 26 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"263"},{"groupId":"OG001","value":"266"},{"groupId":"OG002","value":"259"},{"groupId":"OG003","value":"127"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.80","spread":"0.52"},{"groupId":"OG001","value":"2.80","spread":"0.51"},{"groupId":"OG002","value":"1.18","spread":"0.52"},{"groupId":"OG003","value":"0.61","spread":"0.70"}]}]}]},{"type":"SECONDARY","title":"Change in Baseline to 52 Weeks on Pulse Rate","description":"Seated pulse rate was measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.","populationDescription":"Participants who were randomized at baseline to LY2189265 or Exenatide and received at least 1 dose of study drug with evaluable seated pulse rate data.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"beats per minute (bpm)","timeFrame":"Baseline, 52 weeks","groups":[{"id":"OG000","title":"1.5 mg LY2189265","description":"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG001","title":"0.75 mg LY2189265","description":"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG002","title":"Exenatide","description":"Exenatide: 5 micrograms (mcg), subcutaneous (SC), twice daily for 4 weeks, followed by 10 mcg, SC, twice daily for 48 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"248"},{"groupId":"OG001","value":"256"},{"groupId":"OG002","value":"238"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.68","spread":"0.56"},{"groupId":"OG001","value":"1.56","spread":"0.55"},{"groupId":"OG002","value":"1.15","spread":"0.56"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to 26 Weeks on Blood Pressure","description":"Seated systolic blood pressure (SBP) and seated diastolic blood pressure (DBP) were measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.","populationDescription":"Participants who were randomized and received at least one dose of LY2189265, Exenatide, or Placebo with evaluable blood pressure data.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"millimeters of mercury (mmHg)","timeFrame":"Baseline, 26 weeks","groups":[{"id":"OG000","title":"1.5 mg LY2189265","description":"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG001","title":"0.75 mg LY2189265","description":"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG002","title":"Exenatide","description":"Exenatide: 5 micrograms (mcg), subcutaneous (SC), twice daily for 4 weeks, followed by 10 mcg, SC, twice daily for 48 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG003","title":"Placebo","description":"Placebo: subcutaneous (SC), once weekly for 26 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 26 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 26 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"279"},{"groupId":"OG001","value":"280"},{"groupId":"OG002","value":"276"},{"groupId":"OG003","value":"141"}]}],"classes":[{"title":"Seated SBP (n=263, 266, 259, 127)","categories":[{"measurements":[{"groupId":"OG000","value":"0.11","spread":"0.83"},{"groupId":"OG001","value":"-0.36","spread":"0.82"},{"groupId":"OG002","value":"0.06","spread":"0.83"},{"groupId":"OG003","value":"3.40","spread":"1.13"}]}]},{"title":"Seated DBP (n=263, 266, 259, 127)","categories":[{"measurements":[{"groupId":"OG000","value":"0.76","spread":"0.55"},{"groupId":"OG001","value":"0.56","spread":"0.54"},{"groupId":"OG002","value":"-0.11","spread":"0.55"},{"groupId":"OG003","value":"1.25","spread":"0.75"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to 52 Weeks on Blood Pressure","description":"Seated systolic blood pressure (SBP) and seated diastolic blood pressure (DBP) were measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.","populationDescription":"Participants who were randomized at baseline to LY2189265 or Exenatide and received at least 1 dose of study drug with evaluable blood pressure data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Error","unitOfMeasure":"millimeters of mercury (mmHg)","timeFrame":"Baseline, 52 weeks","groups":[{"id":"OG000","title":"1.5 mg LY2189265","description":"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG001","title":"0.75 mg LY2189265","description":"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG002","title":"Exenatide","description":"Exenatide: 5 micrograms (mcg), subcutaneous (SC), twice daily for 4 weeks, followed by 10 mcg, SC, twice daily for 48 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"279"},{"groupId":"OG001","value":"280"},{"groupId":"OG002","value":"276"}]}],"classes":[{"title":"Seated SBP (n=248, 256, 238)","categories":[{"measurements":[{"groupId":"OG000","value":"0.83","spread":"0.87"},{"groupId":"OG001","value":"1.62","spread":"0.85"},{"groupId":"OG002","value":"0.02","spread":"0.88"}]}]},{"title":"Seated DBP (n=248, 256, 238)","categories":[{"measurements":[{"groupId":"OG000","value":"0.89","spread":"0.57"},{"groupId":"OG001","value":"0.76","spread":"0.57"},{"groupId":"OG002","value":"0.02","spread":"0.58"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Adjudicated Pancreatitis at 26 Weeks","description":"The number of participants with pancreatitis confirmed by adjudication is summarized cumulatively at 26 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.","populationDescription":"Participants who were randomized and received at least 1 dose of LY2189265, Exenatide, or Placebo.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Baseline through 26 weeks","groups":[{"id":"OG000","title":"1.5 mg LY2189265","description":"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG001","title":"0.75 mg LY2189265","description":"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG002","title":"Exenatide","description":"Exenatide: 5 micrograms (mcg), subcutaneous (SC), twice daily for 4 weeks, followed by 10 mcg, SC, twice daily for 48 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG003","title":"Placebo","description":"Placebo: subcutaneous (SC), once weekly for 26 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 26 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 26 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"279"},{"groupId":"OG001","value":"280"},{"groupId":"OG002","value":"276"},{"groupId":"OG003","value":"141"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Adjudicated Pancreatitis at 52 Weeks","description":"The number of participants with pancreatitis confirmed by adjudication is summarized cumulatively at 52 weeks, with the exception of the Placebo/1.5 mg LY2189265 and Placebo/0.75 mg LY2189265 treatment groups, which include only participants with confirmed pancreatitis during treatment with LY2189265 (26 weeks through 52 weeks). A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.","populationDescription":"Participants who were randomized at baseline to LY2189265, Exenatide, or Placebo and received at least 1 dose of study drug.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Baseline through 52 weeks","groups":[{"id":"OG000","title":"1.5 mg LY2189265","description":"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG001","title":"0.75 mg LY2189265","description":"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG002","title":"Exenatide","description":"Exenatide: 5 micrograms (mcg), subcutaneous (SC), twice daily for 4 weeks, followed by 10 mcg, SC, twice daily for 48 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG003","title":"Placebo/1.5 mg LY2189265","description":"Placebo: subcutaneous (SC), once weekly for 26 weeks\n\nLY2189265 (Dulaglutide): 1.5 milligrams (mg), SC, once weekly from week 26 through week 52\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG004","title":"Placebo/0.75 mg LY2189265","description":"Placebo: subcutaneous (SC), once weekly for 26 weeks\n\nLY2189265 (Dulaglutide): 0.75 milligrams (mg), SC, once weekly from week 26 through week 52\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"279"},{"groupId":"OG001","value":"280"},{"groupId":"OG002","value":"276"},{"groupId":"OG003","value":"62"},{"groupId":"OG004","value":"62"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to 26 Weeks on Pancreatic Enzymes","description":"Amylase (total and pancreas-derived) and lipase concentrations were measured.","populationDescription":"Participants who were randomized and received at least 1 dose of LY2189265, Exenatide, or Placebo with evaluable pancreatic enzyme data. Last observation carried forward (LOCF) was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","unitOfMeasure":"units per liter","timeFrame":"Baseline, 26 weeks","groups":[{"id":"OG000","title":"1.5 mg LY2189265","description":"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG001","title":"0.75 mg LY2189265","description":"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG002","title":"Exenatide","description":"Exenatide: 5 micrograms (mcg), subcutaneous (SC), twice daily for 4 weeks, followed by 10 mcg, SC, twice daily for 48 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG003","title":"Placebo","description":"Placebo: subcutaneous (SC), once weekly for 26 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 26 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 26 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"279"},{"groupId":"OG001","value":"280"},{"groupId":"OG002","value":"276"},{"groupId":"OG003","value":"141"}]}],"classes":[{"title":"Amylase, Total (n=253, 253, 254, 127)","categories":[{"measurements":[{"groupId":"OG000","value":"12.50","spread":"26.55","lowerLimit":"-3.57","upperLimit":"28.85"},{"groupId":"OG001","value":"3.28","spread":"24.24","lowerLimit":"-9.88","upperLimit":"20.00"},{"groupId":"OG002","value":"5.56","spread":"26.61","lowerLimit":"-9.52","upperLimit":"18.46"},{"groupId":"OG003","value":"-3.33","spread":"27.51","lowerLimit":"-15.79","upperLimit":"11.36"}]}]},{"title":"Amylase, Pancreas-derived (n=237, 247, 246, 122)","categories":[{"measurements":[{"groupId":"OG000","value":"14.81","lowerLimit":"0.00","upperLimit":"35.00"},{"groupId":"OG001","value":"10.34","lowerLimit":"-5.88","upperLimit":"26.67"},{"groupId":"OG002","value":"5.56","lowerLimit":"-7.14","upperLimit":"21.05"},{"groupId":"OG003","value":"-3.77","lowerLimit":"-13.33","upperLimit":"13.64"}]}]},{"title":"Lipase (n=198, 203, 222, 114)","categories":[{"measurements":[{"groupId":"OG000","value":"10.34","lowerLimit":"-7.50","upperLimit":"29.41"},{"groupId":"OG001","value":"0.00","lowerLimit":"-15.91","upperLimit":"23.08"},{"groupId":"OG002","value":"3.94","lowerLimit":"-10.26","upperLimit":"23.08"},{"groupId":"OG003","value":"-9.53","lowerLimit":"-23.33","upperLimit":"6.67"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to 52 Weeks on Pancreatic Enzymes","description":"Amylase (total and pancreas-derived) and lipase concentrations were measured.","populationDescription":"Participants who were randomized at baseline to LY2189265 or Exenatide and received at least 1 dose of study drug with evaluable pancreatic enzyme data. Last observation carried forward (LOCF) was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","unitOfMeasure":"units per liter","timeFrame":"Baseline, 52 weeks","groups":[{"id":"OG000","title":"1.5 mg LY2189265","description":"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG001","title":"0.75 mg LY2189265","description":"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG002","title":"Exenatide","description":"Exenatide: 5 micrograms (mcg), subcutaneous (SC), twice daily for 4 weeks, followed by 10 mcg, SC, twice daily for 48 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"279"},{"groupId":"OG001","value":"280"},{"groupId":"OG002","value":"276"}]}],"classes":[{"title":"Amylase, Total (n=255, 263, 261)","categories":[{"measurements":[{"groupId":"OG000","value":"9.21","lowerLimit":"-4.95","upperLimit":"23.19"},{"groupId":"OG001","value":"2.78","lowerLimit":"-11.67","upperLimit":"17.50"},{"groupId":"OG002","value":"2.38","lowerLimit":"-11.86","upperLimit":"15.22"}]}]},{"title":"Amylase, Pancreas-derived (n=236, 253, 246)","categories":[{"measurements":[{"groupId":"OG000","value":"16.67","lowerLimit":"0.00","upperLimit":"35.60"},{"groupId":"OG001","value":"7.69","lowerLimit":"-8.70","upperLimit":"28.00"},{"groupId":"OG002","value":"7.85","lowerLimit":"-8.82","upperLimit":"26.67"}]}]},{"title":"Lipase (n=201, 205, 221)","categories":[{"measurements":[{"groupId":"OG000","value":"5.45","lowerLimit":"-7.69","upperLimit":"26.92"},{"groupId":"OG001","value":"0.00","lowerLimit":"-18.18","upperLimit":"15.63"},{"groupId":"OG002","value":"3.57","lowerLimit":"-13.95","upperLimit":"22.58"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to 26 Weeks on Serum Calcitonin","populationDescription":"Participants who were randomized and received at least 1 dose of LY2189265, Exenatide, or Placebo with evaluable serum calcitonin data. Last observation carried forward (LOCF) was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"picograms per milliliter (pg/mL)","timeFrame":"Baseline, 26 weeks","groups":[{"id":"OG000","title":"1.5 mg LY2189265","description":"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG001","title":"0.75 mg LY2189265","description":"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG002","title":"Exenatide","description":"Exenatide: 5 micrograms (mcg), subcutaneous (SC), twice daily for 4 weeks, followed by 10 mcg, SC, twice daily for 48 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG003","title":"Placebo","description":"Placebo: subcutaneous (SC), once weekly for 26 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 26 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 26 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"275"},{"groupId":"OG001","value":"277"},{"groupId":"OG002","value":"272"},{"groupId":"OG003","value":"139"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.20","spread":"1.20"},{"groupId":"OG001","value":"0.22","spread":"1.91"},{"groupId":"OG002","value":"0.05","spread":"1.48"},{"groupId":"OG003","value":"0.05","spread":"0.89"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to 52 Weeks on Serum Calcitonin","populationDescription":"Participants who were randomized at baseline to LY2189265 or Exenatide and received at least 1 dose of study drug with evaluable serum calcitonin data. Last observation carried forward (LOCF) was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"picograms per milliliter (pg/mL)","timeFrame":"Baseline, 52 weeks","groups":[{"id":"OG000","title":"1.5 mg LY2189265","description":"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG001","title":"0.75 mg LY2189265","description":"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG002","title":"Exenatide","description":"Exenatide: 5 micrograms (mcg), subcutaneous (SC), twice daily for 4 weeks, followed by 10 mcg, SC, twice daily for 48 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"275"},{"groupId":"OG001","value":"277"},{"groupId":"OG002","value":"272"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.21","spread":"1.29"},{"groupId":"OG001","value":"0.05","spread":"1.79"},{"groupId":"OG002","value":"0.10","spread":"1.67"}]}]}]},{"type":"SECONDARY","title":"Number of Self-reported Hypoglycemic Events at 26 Weeks","description":"Hypoglycemic events (HE) were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of less than or equal to 3.9 millimoles/liter \\[mmol/L\\]), asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of less than or equal to 3.9 mmol/L), nocturnal (defined as any hypoglycemic event that occurred between bedtime and waking), or probable symptomatic (defined as events during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). The number of self-reported hypoglycemic events is summarized cumulatively at 26 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.","populationDescription":"Participants who were randomized and received at least 1 dose of LY2189265, Exenatide, or Placebo.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"events","timeFrame":"Baseline through 26 weeks","groups":[{"id":"OG000","title":"1.5 mg LY2189265","description":"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG001","title":"0.75 mg LY2189265","description":"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG002","title":"Exenatide","description":"Exenatide: 5 micrograms (mcg), subcutaneous (SC), twice daily for 4 weeks, followed by 10 mcg, SC, twice daily for 48 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG003","title":"Placebo","description":"Placebo: subcutaneous (SC), once weekly for 26 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 26 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 26 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"279"},{"groupId":"OG001","value":"280"},{"groupId":"OG002","value":"276"},{"groupId":"OG003","value":"141"}]}],"classes":[{"title":"Severe HE","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}]}]},{"title":"Documented Symptomatic HE","categories":[{"measurements":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"25"},{"groupId":"OG002","value":"146"},{"groupId":"OG003","value":"4"}]}]},{"title":"Asymptomatic HE","categories":[{"measurements":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"95"},{"groupId":"OG002","value":"51"},{"groupId":"OG003","value":"5"}]}]},{"title":"Nocturnal HE","categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"31"},{"groupId":"OG003","value":"6"}]}]},{"title":"Probable Symptomatic HE","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"}]}]}]},{"type":"SECONDARY","title":"Number of Self-reported Hypoglycemic Events at 52 Weeks","description":"Hypoglycemic events (HE) were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of less than or equal to 3.9 millimoles/liter \\[mmol/L\\]), asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of less than or equal to 3.9 mmol/L), nocturnal (defined as any hypoglycemic event that occurred between bedtime and waking), or probable symptomatic (defined as events during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). The number of self-reported hypoglycemic events is summarized cumulatively at 52 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.","populationDescription":"Participants who were randomized at baseline to LY2189265 or Exenatide and received at least 1 dose of study drug.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"events","timeFrame":"Baseline through 52 weeks","groups":[{"id":"OG000","title":"1.5 mg LY2189265","description":"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG001","title":"0.75 mg LY2189265","description":"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG002","title":"Exenatide","description":"Exenatide: 5 micrograms (mcg), subcutaneous (SC), twice daily for 4 weeks, followed by 10 mcg, SC, twice daily for 48 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"279"},{"groupId":"OG001","value":"280"},{"groupId":"OG002","value":"276"}]}],"classes":[{"title":"Severe HE","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"}]}]},{"title":"Documented Symptomatic HE","categories":[{"measurements":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"39"},{"groupId":"OG002","value":"205"}]}]},{"title":"Asymptomatic HE","categories":[{"measurements":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"157"},{"groupId":"OG002","value":"98"}]}]},{"title":"Nocturnal HE","categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"29"},{"groupId":"OG002","value":"57"}]}]},{"title":"Probable Symptomatic HE","categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"22"},{"groupId":"OG002","value":"4"}]}]}]},{"type":"SECONDARY","title":"Rate of Self-reported Hypoglycemic Events at 26 Weeks","description":"Hypoglycemic events (HE) were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of equal to or less than 3.9 millimoles/liter \\[mmol/L\\]), asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of equal to or less than 3.9 mmol/L), nocturnal (defined as any hypoglycemic event that occurred between bedtime and waking), or probable symptomatic (defined as events during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). The 1-year adjusted rate of hypoglycemic events is summarized cumulatively at 26 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.","populationDescription":"Participants who were randomized and received at least one dose of LY2189265, Exenatide, or Placebo. Only pre-rescue measurements were used.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"events per participant per year","timeFrame":"Baseline through 26 weeks","groups":[{"id":"OG000","title":"1.5 mg LY2189265","description":"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG001","title":"0.75 mg LY2189265","description":"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG002","title":"Exenatide","description":"Exenatide: 5 micrograms (mcg), subcutaneous (SC), twice daily for 4 weeks, followed by 10 mcg, SC, twice daily for 48 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG003","title":"Placebo","description":"Placebo: subcutaneous (SC), once weekly for 26 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 26 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 26 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"279"},{"groupId":"OG001","value":"280"},{"groupId":"OG002","value":"276"},{"groupId":"OG003","value":"141"}]}],"classes":[{"title":"Severe HE","categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"},{"groupId":"OG001","value":"0.00","spread":"0.00"},{"groupId":"OG002","value":"0.01","spread":"0.12"},{"groupId":"OG003","value":"0.00","spread":"0.00"}]}]},{"title":"Documented symptomatic HE","categories":[{"measurements":[{"groupId":"OG000","value":"0.22","spread":"1.94"},{"groupId":"OG001","value":"0.18","spread":"0.97"},{"groupId":"OG002","value":"1.07","spread":"4.90"},{"groupId":"OG003","value":"0.06","spread":"0.48"}]}]},{"title":"Asymptomatic HE","categories":[{"measurements":[{"groupId":"OG000","value":"0.19","spread":"1.13"},{"groupId":"OG001","value":"0.69","spread":"4.74"},{"groupId":"OG002","value":"0.38","spread":"1.74"},{"groupId":"OG003","value":"0.27","spread":"2.44"}]}]},{"title":"Nocturnal HE","categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":"0.60"},{"groupId":"OG001","value":"0.19","spread":"1.74"},{"groupId":"OG002","value":"0.23","spread":"1.16"},{"groupId":"OG003","value":"0.27","spread":"2.51"}]}]},{"title":"Probable symptomatic HE","categories":[{"measurements":[{"groupId":"OG000","value":"0.04","spread":"0.37"},{"groupId":"OG001","value":"0.24","spread":"2.44"},{"groupId":"OG002","value":"0.02","spread":"0.21"},{"groupId":"OG003","value":"0.04","spread":"0.51"}]}]}]},{"type":"SECONDARY","title":"Rate of Self-reported Hypoglycemic Events at 52 Weeks","description":"Hypoglycemic events (HE) were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of equal to or less than millimoles/liter \\[mmol/L\\]), asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of equal to or less than 3.9 mmol/L), nocturnal (defined as any hypoglycemic event that occurred between bedtime and waking), or probable symptomatic (defined as events during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). The 1-year adjusted rate of hypoglycemic events is summarized cumulatively at 52 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.","populationDescription":"Participants who were randomized at baseline to LY2189265 or Exenatide and received at least 1 dose of study drug. Only pre-rescue measurements were used.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"events per participant per year","timeFrame":"Baseline through 52 weeks","groups":[{"id":"OG000","title":"1.5 mg LY2189265","description":"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG001","title":"0.75 mg LY2189265","description":"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG002","title":"Exenatide","description":"Exenatide: 5 micrograms (mcg), subcutaneous (SC), twice daily for 4 weeks, followed by 10 mcg, SC, twice daily for 48 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"279"},{"groupId":"OG001","value":"280"},{"groupId":"OG002","value":"276"}]}],"classes":[{"title":"Severe HE","categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"},{"groupId":"OG001","value":"0.00","spread":"0.00"},{"groupId":"OG002","value":"0.01","spread":"0.09"}]}]},{"title":"Documented symptomatic HE","categories":[{"measurements":[{"groupId":"OG000","value":"0.19","spread":"1.23"},{"groupId":"OG001","value":"0.14","spread":"0.78"},{"groupId":"OG002","value":"0.76","spread":"3.18"}]}]},{"title":"Asymptomatic HE","categories":[{"measurements":[{"groupId":"OG000","value":"0.17","spread":"1.05"},{"groupId":"OG001","value":"0.56","spread":"3.57"},{"groupId":"OG002","value":"0.37","spread":"1.81"}]}]},{"title":"Nocturnal HE","categories":[{"measurements":[{"groupId":"OG000","value":"0.07","spread":"0.63"},{"groupId":"OG001","value":"0.19","spread":"1.72"},{"groupId":"OG002","value":"0.21","spread":"1.06"}]}]},{"title":"Probable symptomatic HE","categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"0.26"},{"groupId":"OG001","value":"0.21","spread":"2.38"},{"groupId":"OG002","value":"0.02","spread":"0.16"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Requiring Rescue Therapy Due to Hyperglycemia at 26 Weeks","description":"Rescue therapy was defined as any additional therapeutic intervention in participants who developed persistent, severe hyperglycemia despite full compliance with the assigned therapeutic regimen, or initiation of an alternative antihyperglycemic medication following study drug discontinuation. Participants who had no rescue therapy within specified study period were considered as censored observations at the last available contact date up to specified study period. Time to start first new glucose-lowering intervention due to hyperglycemia (\"rescue therapy\") was analyzed between the groups using the semi-parametric proportional hazard regression model with treatment group and country as fixed effects and baseline glycosylated hemoglobin (HbA1c) as a covariate.","populationDescription":"Participants who were randomized and received at least 1 dose of LY2189265, Exenatide, or Placebo.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Baseline through 26 weeks","groups":[{"id":"OG000","title":"1.5 mg LY2189265","description":"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG001","title":"0.75 mg LY2189265","description":"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG002","title":"Exenatide","description":"Exenatide: 5 micrograms (mcg), subcutaneous (SC), twice daily for 4 weeks, followed by 10 mcg, SC, twice daily for 48 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG003","title":"Placebo","description":"Placebo: subcutaneous (SC), once weekly for 26 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 26 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 26 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"279"},{"groupId":"OG001","value":"280"},{"groupId":"OG002","value":"276"},{"groupId":"OG003","value":"141"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"22"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Requiring Rescue Therapy Due to Hyperglycemia at 52 Weeks","description":"Rescue therapy was defined as any additional therapeutic intervention in participants who developed persistent, severe hyperglycemia despite full compliance with the assigned therapeutic regimen, or initiation of an alternative antihyperglycemic medication following study drug discontinuation. Participants who had no rescue therapy within specified study period were considered as censored observations at the last available contact date up to specified study period. Time to start first new glucose-lowering intervention due to hyperglycemia (\"rescue therapy\") was analyzed between the groups using the semi-parametric proportional hazard regression model with treatment group and country as fixed effects and baseline glycosylated hemoglobin (HbA1c) as a covariate.","populationDescription":"Participants who were randomized at baseline to LY2189265 or Exenatide and received at least 1 dose of study drug.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Baseline through 52 weeks","groups":[{"id":"OG000","title":"1.5 mg LY2189265","description":"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG001","title":"0.75 mg LY2189265","description":"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG002","title":"Exenatide","description":"Exenatide: 5 micrograms (mcg), subcutaneous (SC), twice daily for 4 weeks, followed by 10 mcg, SC, twice daily for 48 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"279"},{"groupId":"OG001","value":"280"},{"groupId":"OG002","value":"276"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"31"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With LY2189265 Antibodies at 26 Weeks","description":"LY2189265 (Dulaglutide) anti-drug antibodies (ADA) were assessed. The number of participants with initial postbaseline detection of treatment emergent (defined as a 4-fold increase in the ADA titer from baseline) LY2189265 ADA were summarized.","populationDescription":"Participants who were randomized and received at least one dose of LY2189265, Exenatide, or Placebo with evaluable LY2189265 ADA data. In the clinically evaluated dose range of LY2189265, no dose effect on the magnitude of the anti-LY2189265 immune response was observed. Therefore, results were combined for the 0.75 mg and 1.5 mg LY2189265 groups.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Baseline through 26 weeks","groups":[{"id":"OG000","title":"0.75 mg LY2189265 or 1.5 mg LY2189265","description":"LY2189265 (Dulaglutide): 0.75 or 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG001","title":"Exenatide","description":"Exenatide: 5 micrograms (mcg), subcutaneous (SC), twice daily for 4 weeks, followed by 10 mcg, SC, twice daily for 48 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG002","title":"Placebo","description":"Placebo: subcutaneous (SC), once weekly for 26 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 26 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 26 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"559"},{"groupId":"OG001","value":"276"},{"groupId":"OG002","value":"141"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"2"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With LY2189265 Antibodies at 52 Weeks and 4 Weeks After Last Dose of Study Drug","description":"LY2189265 (Dulaglutide) anti-drug antibodies (ADA) were assessed. The number of participants with initial postbaseline detection of treatment emergent (defined as a 4-fold increase in the ADA titer from baseline) LY2189265 ADA were summarized.","populationDescription":"Participants who were randomized and received at least one dose of LY2189265, Exenatide, or Placebo with evaluable LY2189265 ADA data. In the clinically evaluated dose range of LY2189265, no dose effect on the magnitude of the anti-LY2189265 immune response was observed. Therefore, results were combined for the 0.75 mg and 1.5 mg LY2189265 groups.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"26 weeks through 52 weeks and 53 weeks through 4 weeks after last dose","groups":[{"id":"OG000","title":"0.75 mg LY2189265 or 1.5 mg LY2189265","description":"LY2189265 (Dulaglutide): 0.75 or 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG001","title":"Exenatide","description":"Exenatide: 5 micrograms (mcg), subcutaneous (SC), twice daily for 4 weeks, followed by 10 mcg, SC, twice daily for 48 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG002","title":"Placebo/0.75 mg LY2189265 or 1.5 mg LY2189265","description":"Placebo: subcutaneous (SC), once weekly for 26 weeks\n\nLY2189265 (Dulaglutide): 0.75 or 1.5 milligrams (mg), SC, once weekly from week 26 through week 52\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"552"},{"groupId":"OG001","value":"270"},{"groupId":"OG002","value":"123"}]}],"classes":[{"title":"52 weeks","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"}]}]},{"title":"4 weeks after last study dose","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment Emergent Adverse Events at 26 Weeks","description":"A treatment-emergent adverse event (TEAE) was defined as an event that first occurs or worsens (increases in severity) after baseline regardless of causality or severity. The number of participants with one or more TEAE is summarized cumulatively at 26 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.","populationDescription":"Participants who were randomized and received at least 1 dose of LY2189265, Exenatide, or Placebo.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Baseline through 26 weeks","groups":[{"id":"OG000","title":"1.5 mg LY2189265","description":"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG001","title":"0.75 mg LY2189265","description":"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG002","title":"Exenatide","description":"Exenatide: 5 micrograms (mcg), subcutaneous (SC), twice daily for 4 weeks, followed by 10 mcg, SC, twice daily for 48 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG003","title":"Placebo","description":"Placebo: subcutaneous (SC), once weekly for 26 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 26 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 26 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"279"},{"groupId":"OG001","value":"280"},{"groupId":"OG002","value":"276"},{"groupId":"OG003","value":"141"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"215"},{"groupId":"OG001","value":"199"},{"groupId":"OG002","value":"198"},{"groupId":"OG003","value":"104"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment Emergent Adverse Events at 52 Weeks","description":"A treatment-emergent adverse event (TEAE) was defined as an event that first occurs or worsens (increases in severity) after baseline regardless of causality or severity. The number of participants with one or more TEAE is summarized cumulatively at 52 weeks, with the exception of the Placebo/1.5 mg LY2189265 and Placebo/0.75 mg LY2189265 treatment groups, which include only TEAEs that occurred during treatment with LY2189265 (26 weeks through 52 weeks). A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.","populationDescription":"Participants who were randomized at baseline to LY2189265, Exenatide, or Placebo and received at least 1 dose of study drug.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Baseline through 52 weeks","groups":[{"id":"OG000","title":"1.5 mg LY2189265","description":"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG001","title":"0.75 mg LY2189265","description":"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG002","title":"Exenatide","description":"Exenatide: 5 micrograms (mcg), subcutaneous (SC), twice daily for 4 weeks, followed by 10 mcg, SC, twice daily for 48 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG003","title":"Placebo/1.5 mg LY2189265","description":"Placebo: subcutaneous (SC), once weekly for 26 weeks\n\nLY2189265 (Dulaglutide): 1.5 milligrams (mg), SC, once weekly from week 26 through week 52\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG004","title":"Placebo/0.75 mg LY2189265","description":"Placebo: subcutaneous (SC), once weekly for 26 weeks\n\nLY2189265 (Dulaglutide): 0.75 milligrams (mg), SC, once weekly from week 26 through week 52\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"279"},{"groupId":"OG001","value":"280"},{"groupId":"OG002","value":"276"},{"groupId":"OG003","value":"62"},{"groupId":"OG004","value":"62"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"226"},{"groupId":"OG001","value":"220"},{"groupId":"OG002","value":"221"},{"groupId":"OG003","value":"47"},{"groupId":"OG004","value":"41"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to 26 Weeks in Hematological and Biochemical Lab Values","populationDescription":"Participants who were randomized and received at least 1 dose of LY2189265, Exenatide, or Placebo.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","timeFrame":"Baseline, 26 weeks","groups":[{"id":"OG000","title":"1.5 mg LY2189265","description":"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG001","title":"0.75 mg LY2189265","description":"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG002","title":"Exenatide","description":"Exenatide: 5 micrograms (mcg), subcutaneous (SC), twice daily for 4 weeks, followed by 10 mcg, SC, twice daily for 48 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG003","title":"Placebo","description":"Placebo: subcutaneous (SC), once weekly for 26 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 26 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 26 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"279"},{"groupId":"OG001","value":"280"},{"groupId":"OG002","value":"276"},{"groupId":"OG003","value":"141"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA","comment":"No clinically relevant changes from baseline to 26 weeks in hematological and biochemical laboratory values were noted, with the exception of pancreatic enzymes and calcitonin measures, which are reported in separate outcome measures."},{"groupId":"OG001","value":"NA","spread":"NA","comment":"No clinically relevant changes from baseline to 26 weeks in hematological and biochemical laboratory values were noted, with the exception of pancreatic enzymes and calcitonin measures, which are reported in separate outcome measures."},{"groupId":"OG002","value":"NA","spread":"NA","comment":"No clinically relevant changes from baseline to 26 weeks in hematological and biochemical laboratory values were noted, with the exception of pancreatic enzymes and calcitonin measures, which are reported in separate outcome measures."},{"groupId":"OG003","value":"NA","spread":"NA","comment":"No clinically relevant changes from baseline to 26 weeks in hematological and biochemical laboratory values were noted, with the exception of pancreatic enzymes and calcitonin measures, which are reported in separate outcome measures."}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to 52 Weeks in Hematological and Biochemical Lab Values","populationDescription":"Participants who were randomized at baseline to LY2189265 or Exenatide and received at least 1 dose of study drug.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","timeFrame":"Baseline, 52 weeks","groups":[{"id":"OG000","title":"1.5 mg LY2189265","description":"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG001","title":"0.75 mg LY2189265","description":"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG002","title":"Exenatide","description":"Exenatide: 5 micrograms (mcg), subcutaneous (SC), twice daily for 4 weeks, followed by 10 mcg, SC, twice daily for 48 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"279"},{"groupId":"OG001","value":"280"},{"groupId":"OG002","value":"276"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA","comment":"No clinically relevant changes from baseline to 26 weeks in hematological and biochemical laboratory values were noted, with the exception of pancreatic enzymes and calcitonin measures, which are reported in separate outcome measures."},{"groupId":"OG001","value":"NA","spread":"NA","comment":"No clinically relevant changes from baseline to 26 weeks in hematological and biochemical laboratory values were noted, with the exception of pancreatic enzymes and calcitonin measures, which are reported in separate outcome measures."},{"groupId":"OG002","value":"NA","spread":"NA","comment":"No clinically relevant changes from baseline to 26 weeks in hematological and biochemical laboratory values were noted, with the exception of pancreatic enzymes and calcitonin measures, which are reported in separate outcome measures."}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to 26 Weeks in N Terminal Pro Brain Natriuretic Peptide (NT-proBNP)","populationDescription":"Participants who were randomized and received at least 1 dose of LY2189265, Exenatide, or Placebo with evaluable NT-proBNP data. Last observation carried forward (LOCF) was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","unitOfMeasure":"picograms per milliliter (pg/mL)","timeFrame":"Baseline, 26 weeks","groups":[{"id":"OG000","title":"1.5 mg LY2189265","description":"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG001","title":"0.75 mg LY2189265","description":"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG002","title":"Exenatide","description":"Exenatide: 5 micrograms (mcg), subcutaneous (SC), twice daily for 4 weeks, followed by 10 mcg, SC, twice daily for 48 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG003","title":"Placebo","description":"Placebo: subcutaneous (SC), once weekly for 26 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 26 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 26 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"255"},{"groupId":"OG001","value":"254"},{"groupId":"OG002","value":"246"},{"groupId":"OG003","value":"119"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.77","spread":"91.13","lowerLimit":"-30.45","upperLimit":"15.22"},{"groupId":"OG001","value":"-2.96","spread":"189.94","lowerLimit":"-22.83","upperLimit":"19.45"},{"groupId":"OG002","value":"-3.38","spread":"208.92","lowerLimit":"-31.29","upperLimit":"18.61"},{"groupId":"OG003","value":"-0.85","spread":"133.04","lowerLimit":"-25.37","upperLimit":"17.76"}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetics: Area Under the Concentration Curve (AUC) for LY2189265","description":"Evaluable pharmacokinetic concentrations from the 4-week, 13-week, 26-week, and 52-week timepoints were combined and utilized in a population approach to determine the population mean estimate and standard deviation at steady-state.","populationDescription":"Participants who were randomized at baseline to LY2189265 and received at least 1 dose of study drug with evaluable AUC data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"nanogram hours per milliliter (ng*hr/mL)","timeFrame":"4 weeks, 13 weeks, 26 weeks, and 52 weeks","groups":[{"id":"OG000","title":"1.5 mg LY2189265","description":"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"},{"id":"OG001","title":"0.75 mg LY2189265","description":"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"325"},{"groupId":"OG001","value":"321"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12383","spread":"5433"},{"groupId":"OG001","value":"6627","spread":"2487"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","eventGroups":[{"id":"EG000","title":"0.75 mg LY2189265 (Baseline Through 26 Weeks)","description":"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks","seriousNumAffected":15,"seriousNumAtRisk":280,"otherNumAffected":194,"otherNumAtRisk":280},{"id":"EG001","title":"1.5 mg LY2189265 (Baseline Through 26 Weeks)","description":"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks","seriousNumAffected":12,"seriousNumAtRisk":279,"otherNumAffected":215,"otherNumAtRisk":279},{"id":"EG002","title":"Exenatide (Baseline Through 26 Weeks)","description":"Exenatide: 5 micrograms (mcg), subcutaneous (SC), twice daily for 4 weeks, followed by 10 mcg, SC, twice daily for 48 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks","seriousNumAffected":15,"seriousNumAtRisk":278,"otherNumAffected":196,"otherNumAtRisk":278},{"id":"EG003","title":"Placebo (Baseline Through 26 Weeks)","description":"Placebo: subcutaneous (SC), once weekly for 26 weeks\n\nLY2189265 (Dulaglutide): After 26 weeks, participants were randomized to receive either 0.75 milligrams (mg) or 1.5 mg, SC, once weekly for an additional 26 weeks (from week 26 through week 52)\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks","seriousNumAffected":12,"seriousNumAtRisk":141,"otherNumAffected":103,"otherNumAtRisk":141},{"id":"EG004","title":"0.75 mg LY2189265 (Baseline Through 56 Weeks)","description":"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks","seriousNumAffected":22,"seriousNumAtRisk":280,"otherNumAffected":218,"otherNumAtRisk":280},{"id":"EG005","title":"1.5 mg LY2189265 (Baseline Through 56 Weeks)","description":"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks","seriousNumAffected":18,"seriousNumAtRisk":279,"otherNumAffected":228,"otherNumAtRisk":279},{"id":"EG006","title":"Exenatide (Baseline Through 56 Weeks)","description":"Exenatide: 5 micrograms (mcg), subcutaneous (SC), twice daily for 4 weeks, followed by 10 mcg, SC, twice daily for 48 weeks\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks","seriousNumAffected":27,"seriousNumAtRisk":278,"otherNumAffected":223,"otherNumAtRisk":278},{"id":"EG007","title":"Placebo/0.75 mg LY2189265 (26 Weeks Through 56 Weeks)","description":"Placebo: subcutaneous (SC), once weekly for 26 weeks\n\nLY2189265 (Dulaglutide): 0.75 milligrams (mg), SC, once weekly from week 26 through week 52\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks\n\nAll events were treatment emergent during the LY2189265 treatment period.","seriousNumAffected":6,"seriousNumAtRisk":62,"otherNumAffected":47,"otherNumAtRisk":62},{"id":"EG008","title":"Placebo/1.5 mg LY2189265 (26 Weeks Through 56 Weeks)","description":"Placebo: subcutaneous (SC), once weekly for 26 weeks\n\nLY2189265 (Dulaglutide): 1.5 milligrams (mg), SC, once weekly from week 26 through week 52\n\nMetformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks\n\nPioglitazone: at least 30 mg/day, oral, for 52 weeks\n\nAll events were treatment emergent during the LY2189265 treatment period.","seriousNumAffected":9,"seriousNumAtRisk":62,"otherNumAffected":55,"otherNumAtRisk":62}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":141},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Event resulted in one death in the 1.5 mg LY2189265 group","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":141},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":279},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Angina pectoris","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":141},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":279},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":141},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":279},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":62},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":62}]},{"term":"Cardiac arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":279},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":141},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":279},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Cardiac failure congestive","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":279},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":141},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":279},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Coronary artery disease","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":278},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":141},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":278},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":279},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":141},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":279},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Myocardial ischaemia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":141},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":62}]},{"term":"Sinus bradycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":278},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":141},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Supraventricular extrasystoles","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":278},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":141},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Ventricular fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":279},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":141},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":279},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Hyperparathyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":141},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Colitis ulcerative","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":278},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":141},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Gastric ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":141},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":279},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":141},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":279},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":141},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Gastrooesophageal sphincter insufficiency","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":141},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Oesophagitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":141},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Pancreatitis acute","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":278},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":141},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Umbilical hernia, obstructive","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":141},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":62}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":141},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":62}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":141},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Gait disturbance","organSystem":"General disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":141},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":279},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":278},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":141},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":279},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Thrombosis in device","organSystem":"General disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":278},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":141},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Biliary colic","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":141},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Cholecystitis acute","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":141},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Cholelithiasis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":279},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":141},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":279},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":141},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":62}]},{"term":"Appendicitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":141},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":280},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":279},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":141},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":279},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":279},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":141},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":279},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Gangrene","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":141},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":279},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":279},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":141},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":279},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Human anaplasmosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":141},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":279},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Localised infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":141},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":62}]},{"term":"Osteomyelitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":141},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG007","numEvents":2,"numAffected":2,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Pelvic abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":278},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":141},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":141},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":280},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":62}]},{"term":"Renal abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":278},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":141},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Sepsis syndrome","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":141},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Staphylococcal infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":278},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":141},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Staphylococcal sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":141},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Subcutaneous abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":141},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":280},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":279},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":278},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":141},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":279},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Humerus fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":278},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":141},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Joint dislocation","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":278},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":141},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Subdural haematoma","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":279},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":141},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":280},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":279},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Tendon injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":141},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":62}]},{"term":"Wound complication","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":141},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":279},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":278},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":141},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Hypoglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":278},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":141},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":278},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":279},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":278},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":141},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":279},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Hypomagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":278},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":141},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Neck pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":279},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":141},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":279},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Osteoarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":278},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":141},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG006","numEvents":3,"numAffected":3,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Colon cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":141},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Gastrointestinal stromal tumour","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":141},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Leiomyoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":141},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":279},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Liposarcoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":141},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Pancreatic carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":279},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":141},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":279},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Prostate cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":168},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":163},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":157},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":83},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":168},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":163},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":157},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":35}]},{"term":"Prostate cancer stage 0","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":168},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":163},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":157},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":168},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":163},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":157},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":35}]},{"term":"Altered state of consciousness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":141},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":279},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":141},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":279},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Convulsion","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":278},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":141},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Peroneal nerve palsy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":278},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":141},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":279},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":141},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":279},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Delirium","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":141},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Impaired self-care","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":141},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Major depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":141},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Suicidal ideation","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":141},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":62}]},{"term":"Bladder perforation","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":279},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":141},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":279},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Nephrolithiasis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":279},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":278},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":141},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":279},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Endometrial hyperplasia","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":112},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":116},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":121},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":112},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":116},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":121},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":26},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":27}]},{"term":"Acute respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":141},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Asthma","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":141},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":141},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":141},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":141},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Knee arthroplasty","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":141},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":280},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Rehabilitation therapy","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":141},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":141},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Hypertensive crisis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":141},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":280},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":279},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":62}]}],"otherEvents":[{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":280},{"groupId":"EG001","numEvents":15,"numAffected":12,"numAtRisk":279},{"groupId":"EG002","numEvents":6,"numAffected":5,"numAtRisk":278},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":141},{"groupId":"EG004","numEvents":6,"numAffected":5,"numAtRisk":280},{"groupId":"EG005","numEvents":19,"numAffected":16,"numAtRisk":279},{"groupId":"EG006","numEvents":6,"numAffected":5,"numAtRisk":278},{"groupId":"EG007","numEvents":2,"numAffected":2,"numAtRisk":62},{"groupId":"EG008","numEvents":6,"numAffected":4,"numAtRisk":62}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":42,"numAffected":22,"numAtRisk":280},{"groupId":"EG001","numEvents":55,"numAffected":31,"numAtRisk":279},{"groupId":"EG002","numEvents":22,"numAffected":16,"numAtRisk":278},{"groupId":"EG003","numEvents":12,"numAffected":8,"numAtRisk":141},{"groupId":"EG004","numEvents":47,"numAffected":26,"numAtRisk":280},{"groupId":"EG005","numEvents":67,"numAffected":37,"numAtRisk":279},{"groupId":"EG006","numEvents":38,"numAffected":22,"numAtRisk":278},{"groupId":"EG007","numEvents":14,"numAffected":5,"numAtRisk":62},{"groupId":"EG008","numEvents":8,"numAffected":8,"numAtRisk":62}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":280},{"groupId":"EG001","numEvents":36,"numAffected":22,"numAtRisk":279},{"groupId":"EG002","numEvents":19,"numAffected":19,"numAtRisk":278},{"groupId":"EG003","numEvents":4,"numAffected":4,"numAtRisk":141},{"groupId":"EG004","numEvents":7,"numAffected":6,"numAtRisk":280},{"groupId":"EG005","numEvents":37,"numAffected":23,"numAtRisk":279},{"groupId":"EG006","numEvents":21,"numAffected":21,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":9,"numAffected":6,"numAtRisk":62}]},{"term":"Flatulence","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":280},{"groupId":"EG001","numEvents":15,"numAffected":14,"numAtRisk":279},{"groupId":"EG002","numEvents":7,"numAffected":6,"numAtRisk":278},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":141},{"groupId":"EG004","numEvents":4,"numAffected":3,"numAtRisk":280},{"groupId":"EG005","numEvents":17,"numAffected":16,"numAtRisk":279},{"groupId":"EG006","numEvents":8,"numAffected":7,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":4,"numAffected":3,"numAtRisk":62}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":60,"numAffected":45,"numAtRisk":280},{"groupId":"EG001","numEvents":108,"numAffected":78,"numAtRisk":279},{"groupId":"EG002","numEvents":86,"numAffected":71,"numAtRisk":278},{"groupId":"EG003","numEvents":8,"numAffected":8,"numAtRisk":141},{"groupId":"EG004","numEvents":64,"numAffected":47,"numAtRisk":280},{"groupId":"EG005","numEvents":114,"numAffected":82,"numAtRisk":279},{"groupId":"EG006","numEvents":101,"numAffected":77,"numAtRisk":278},{"groupId":"EG007","numEvents":6,"numAffected":6,"numAtRisk":62},{"groupId":"EG008","numEvents":17,"numAffected":15,"numAtRisk":62}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":29,"numAffected":17,"numAtRisk":280},{"groupId":"EG001","numEvents":67,"numAffected":47,"numAtRisk":279},{"groupId":"EG002","numEvents":40,"numAffected":30,"numAtRisk":278},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":141},{"groupId":"EG004","numEvents":29,"numAffected":17,"numAtRisk":280},{"groupId":"EG005","numEvents":68,"numAffected":48,"numAtRisk":279},{"groupId":"EG006","numEvents":52,"numAffected":34,"numAtRisk":278},{"groupId":"EG007","numEvents":5,"numAffected":3,"numAtRisk":62},{"groupId":"EG008","numEvents":5,"numAffected":5,"numAtRisk":62}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":12,"numAtRisk":280},{"groupId":"EG001","numEvents":11,"numAffected":10,"numAtRisk":279},{"groupId":"EG002","numEvents":21,"numAffected":21,"numAtRisk":278},{"groupId":"EG003","numEvents":3,"numAffected":2,"numAtRisk":141},{"groupId":"EG004","numEvents":17,"numAffected":13,"numAtRisk":280},{"groupId":"EG005","numEvents":14,"numAffected":13,"numAtRisk":279},{"groupId":"EG006","numEvents":23,"numAffected":22,"numAtRisk":278},{"groupId":"EG007","numEvents":5,"numAffected":3,"numAtRisk":62},{"groupId":"EG008","numEvents":2,"numAffected":2,"numAtRisk":62}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":13,"numAtRisk":280},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":279},{"groupId":"EG002","numEvents":12,"numAffected":11,"numAtRisk":278},{"groupId":"EG003","numEvents":7,"numAffected":7,"numAtRisk":141},{"groupId":"EG004","numEvents":16,"numAffected":15,"numAtRisk":280},{"groupId":"EG005","numEvents":8,"numAffected":8,"numAtRisk":279},{"groupId":"EG006","numEvents":18,"numAffected":17,"numAtRisk":278},{"groupId":"EG007","numEvents":10,"numAffected":9,"numAtRisk":62},{"groupId":"EG008","numEvents":3,"numAffected":3,"numAtRisk":62}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":280},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":279},{"groupId":"EG002","numEvents":8,"numAffected":7,"numAtRisk":278},{"groupId":"EG003","numEvents":4,"numAffected":4,"numAtRisk":141},{"groupId":"EG004","numEvents":12,"numAffected":12,"numAtRisk":280},{"groupId":"EG005","numEvents":13,"numAffected":12,"numAtRisk":279},{"groupId":"EG006","numEvents":16,"numAffected":14,"numAtRisk":278},{"groupId":"EG007","numEvents":5,"numAffected":4,"numAtRisk":62},{"groupId":"EG008","numEvents":3,"numAffected":3,"numAtRisk":62}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":26,"numAffected":23,"numAtRisk":280},{"groupId":"EG001","numEvents":19,"numAffected":18,"numAtRisk":279},{"groupId":"EG002","numEvents":12,"numAffected":12,"numAtRisk":278},{"groupId":"EG003","numEvents":8,"numAffected":8,"numAtRisk":141},{"groupId":"EG004","numEvents":33,"numAffected":26,"numAtRisk":280},{"groupId":"EG005","numEvents":31,"numAffected":28,"numAtRisk":279},{"groupId":"EG006","numEvents":17,"numAffected":16,"numAtRisk":278},{"groupId":"EG007","numEvents":6,"numAffected":5,"numAtRisk":62},{"groupId":"EG008","numEvents":2,"numAffected":2,"numAtRisk":62}]},{"term":"Sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":280},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":279},{"groupId":"EG002","numEvents":10,"numAffected":10,"numAtRisk":278},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":141},{"groupId":"EG004","numEvents":11,"numAffected":9,"numAtRisk":280},{"groupId":"EG005","numEvents":15,"numAffected":12,"numAtRisk":279},{"groupId":"EG006","numEvents":16,"numAffected":16,"numAtRisk":278},{"groupId":"EG007","numEvents":2,"numAffected":2,"numAtRisk":62},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":14,"numAtRisk":280},{"groupId":"EG001","numEvents":13,"numAffected":12,"numAtRisk":279},{"groupId":"EG002","numEvents":14,"numAffected":12,"numAtRisk":278},{"groupId":"EG003","numEvents":8,"numAffected":6,"numAtRisk":141},{"groupId":"EG004","numEvents":31,"numAffected":25,"numAtRisk":280},{"groupId":"EG005","numEvents":18,"numAffected":16,"numAtRisk":279},{"groupId":"EG006","numEvents":29,"numAffected":20,"numAtRisk":278},{"groupId":"EG007","numEvents":6,"numAffected":5,"numAtRisk":62},{"groupId":"EG008","numEvents":5,"numAffected":4,"numAtRisk":62}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":280},{"groupId":"EG001","numEvents":11,"numAffected":11,"numAtRisk":279},{"groupId":"EG002","numEvents":6,"numAffected":6,"numAtRisk":278},{"groupId":"EG003","numEvents":4,"numAffected":4,"numAtRisk":141},{"groupId":"EG004","numEvents":15,"numAffected":13,"numAtRisk":280},{"groupId":"EG005","numEvents":18,"numAffected":16,"numAtRisk":279},{"groupId":"EG006","numEvents":14,"numAffected":14,"numAtRisk":278},{"groupId":"EG007","numEvents":2,"numAffected":2,"numAtRisk":62},{"groupId":"EG008","numEvents":5,"numAffected":5,"numAtRisk":62}]},{"term":"Lipase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":280},{"groupId":"EG001","numEvents":8,"numAffected":7,"numAtRisk":279},{"groupId":"EG002","numEvents":6,"numAffected":5,"numAtRisk":278},{"groupId":"EG003","numEvents":4,"numAffected":4,"numAtRisk":141},{"groupId":"EG004","numEvents":6,"numAffected":6,"numAtRisk":280},{"groupId":"EG005","numEvents":11,"numAffected":9,"numAtRisk":279},{"groupId":"EG006","numEvents":11,"numAffected":9,"numAtRisk":278},{"groupId":"EG007","numEvents":5,"numAffected":4,"numAtRisk":62},{"groupId":"EG008","numEvents":2,"numAffected":2,"numAtRisk":62}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":14,"numAtRisk":280},{"groupId":"EG001","numEvents":23,"numAffected":22,"numAtRisk":279},{"groupId":"EG002","numEvents":8,"numAffected":8,"numAtRisk":278},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":141},{"groupId":"EG004","numEvents":16,"numAffected":15,"numAtRisk":280},{"groupId":"EG005","numEvents":24,"numAffected":23,"numAtRisk":279},{"groupId":"EG006","numEvents":9,"numAffected":9,"numAtRisk":278},{"groupId":"EG007","numEvents":3,"numAffected":2,"numAtRisk":62},{"groupId":"EG008","numEvents":3,"numAffected":3,"numAtRisk":62}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":10,"numAtRisk":280},{"groupId":"EG001","numEvents":9,"numAffected":8,"numAtRisk":279},{"groupId":"EG002","numEvents":12,"numAffected":9,"numAtRisk":278},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":141},{"groupId":"EG004","numEvents":18,"numAffected":17,"numAtRisk":280},{"groupId":"EG005","numEvents":13,"numAffected":12,"numAtRisk":279},{"groupId":"EG006","numEvents":19,"numAffected":13,"numAtRisk":278},{"groupId":"EG007","numEvents":4,"numAffected":3,"numAtRisk":62},{"groupId":"EG008","numEvents":2,"numAffected":2,"numAtRisk":62}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":9,"numAtRisk":280},{"groupId":"EG001","numEvents":11,"numAffected":11,"numAtRisk":279},{"groupId":"EG002","numEvents":9,"numAffected":8,"numAtRisk":278},{"groupId":"EG003","numEvents":9,"numAffected":9,"numAtRisk":141},{"groupId":"EG004","numEvents":16,"numAffected":14,"numAtRisk":280},{"groupId":"EG005","numEvents":16,"numAffected":15,"numAtRisk":279},{"groupId":"EG006","numEvents":14,"numAffected":12,"numAtRisk":278},{"groupId":"EG007","numEvents":4,"numAffected":4,"numAtRisk":62},{"groupId":"EG008","numEvents":6,"numAffected":5,"numAtRisk":62}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":8,"numAtRisk":280},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":279},{"groupId":"EG002","numEvents":8,"numAffected":8,"numAtRisk":278},{"groupId":"EG003","numEvents":7,"numAffected":6,"numAtRisk":141},{"groupId":"EG004","numEvents":14,"numAffected":13,"numAtRisk":280},{"groupId":"EG005","numEvents":12,"numAffected":12,"numAtRisk":279},{"groupId":"EG006","numEvents":17,"numAffected":15,"numAtRisk":278},{"groupId":"EG007","numEvents":4,"numAffected":3,"numAtRisk":62},{"groupId":"EG008","numEvents":4,"numAffected":4,"numAtRisk":62}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":8,"numAtRisk":280},{"groupId":"EG001","numEvents":19,"numAffected":15,"numAtRisk":279},{"groupId":"EG002","numEvents":23,"numAffected":18,"numAtRisk":278},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":141},{"groupId":"EG004","numEvents":11,"numAffected":10,"numAtRisk":280},{"groupId":"EG005","numEvents":24,"numAffected":19,"numAtRisk":279},{"groupId":"EG006","numEvents":30,"numAffected":21,"numAtRisk":278},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":62},{"groupId":"EG008","numEvents":2,"numAffected":2,"numAtRisk":62}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":9,"numAtRisk":280},{"groupId":"EG001","numEvents":26,"numAffected":20,"numAtRisk":279},{"groupId":"EG002","numEvents":27,"numAffected":24,"numAtRisk":278},{"groupId":"EG003","numEvents":9,"numAffected":8,"numAtRisk":141},{"groupId":"EG004","numEvents":15,"numAffected":14,"numAtRisk":280},{"groupId":"EG005","numEvents":36,"numAffected":26,"numAtRisk":279},{"groupId":"EG006","numEvents":31,"numAffected":25,"numAtRisk":278},{"groupId":"EG007","numEvents":6,"numAffected":5,"numAtRisk":62},{"groupId":"EG008","numEvents":7,"numAffected":6,"numAtRisk":62}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":280},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":279},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":278},{"groupId":"EG003","numEvents":7,"numAffected":7,"numAtRisk":141},{"groupId":"EG004","numEvents":8,"numAffected":7,"numAtRisk":280},{"groupId":"EG005","numEvents":9,"numAffected":7,"numAtRisk":279},{"groupId":"EG006","numEvents":3,"numAffected":3,"numAtRisk":278},{"groupId":"EG007","numEvents":4,"numAffected":4,"numAtRisk":62},{"groupId":"EG008","numEvents":5,"numAffected":5,"numAtRisk":62}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 15.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":280},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":279},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":278},{"groupId":"EG003","numEvents":6,"numAffected":6,"numAtRisk":141},{"groupId":"EG004","numEvents":7,"numAffected":7,"numAtRisk":280},{"groupId":"EG005","numEvents":8,"numAffected":8,"numAtRisk":279},{"groupId":"EG006","numEvents":6,"numAffected":6,"numAtRisk":278},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":62},{"groupId":"EG008","numEvents":5,"numAffected":5,"numAtRisk":62}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"GT60","restrictiveAgreement":true},"pointOfContact":{"title":"Chief Medical Officer","organization":"Eli Lilly and Company","phone":"800-545-5979"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-09","removedCountries":["South Korea"]},"conditionBrowseModule":{"meshes":[{"id":"D003924","term":"Diabetes Mellitus, Type 2"}],"ancestors":[{"id":"D003920","term":"Diabetes Mellitus"},{"id":"D044882","term":"Glucose Metabolism Disorders"},{"id":"D008659","term":"Metabolic Diseases"},{"id":"D009750","term":"Nutritional and Metabolic Diseases"},{"id":"D004700","term":"Endocrine System Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C555680","term":"dulaglutide"},{"id":"D000077270","term":"Exenatide"},{"id":"D008687","term":"Metformin"},{"id":"D000077205","term":"Pioglitazone"}],"ancestors":[{"id":"D010455","term":"Peptides"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D014688","term":"Venoms"},{"id":"D045424","term":"Complex Mixtures"},{"id":"D014118","term":"Toxins, Biological"},{"id":"D001685","term":"Biological Factors"},{"id":"D001645","term":"Biguanides"},{"id":"D006146","term":"Guanidines"},{"id":"D000578","term":"Amidines"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D045162","term":"Thiazolidinediones"},{"id":"D013844","term":"Thiazoles"},{"id":"D013457","term":"Sulfur Compounds"},{"id":"D001393","term":"Azoles"},{"id":"D006573","term":"Heterocyclic Compounds, 1-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"}]}},"hasResults":true}